fluorouracil has been researched along with Prostatic Neoplasms in 280 studies
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.
Prostatic Neoplasms: Tumors or cancer of the PROSTATE.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The objective of the trial is to evaluate the efficacy of capecitabine in patients with metastatic hormone-resistant prostate carcinoma (HRPC), in terms of prostate-specific antigen (PSA) response and clinical benefit (decrease of pain or analgesic score) and its safety profile." | 9.11 | Capecitabine in hormone-resistant metastatic prostatic carcinoma - a phase II trial. ( Bauer, J; Bernhard, J; Bonomo, M; Borner, M; Cerny, T; Dietrich, D; Gillessen, S; Gschwend, A; Hanselmann, S; Hering, F; Morant, R; Rochlitz, C; Schmid, HP; Wernli, M, 2004) |
| "Strontium-89 is an established alternative for the alleviation of bone pain in prostate cancer." | 9.11 | Palliation of bone pain in prostate cancer using chemotherapy and strontium-89. A randomized phase II study. ( Edgren, M; Ginman, C; Kälkner, KM; Nilsson, S; Nordström, B; Ryberg, M; Strang, P; Westlin, JE; Zimmermann, R, 2005) |
| "One hundred forty-two patients with progressive, hormonally refractory advanced prostate carcinoma who had not received prior chemotherapy were randomized to receive either combination chemotherapy with 5-fluorouracil (5-FU), doxorubicin, and mitomycin C (FAM) or sequential chemotherapy with the same agents, i." | 9.07 | Chemotherapy for hormonally refractory advanced prostate carcinoma. A comparison of combined versus sequential treatment with mitomycin C, doxorubicin, and 5-fluorouracil. ( Hahn, RG; Krook, JE; Laurie, JA; Mailliard, JA; Morton, RF; Patel, SR; Therneau, TM; Twito, DI; Windschitl, HE, 1992) |
| "Sixty-two patients with metastatic hormonal refractory adenocarcinoma of the prostate received a combination of doxorubicin, mitomycin-C, and 5-fluorouracil (DMF)." | 7.66 | Doxorubicin, mitomycin-C, and 5-fluorouracil (DMF) in the treatment of metastatic hormonal refractory adenocarcinoma of the prostate, with a note on the staging of metastatic prostate cancer. ( Grant, C; Johnson, DE; Logothetis, CJ; Ogden, S; Samuels, ML; Trindade, A; von Eschenbach, AC, 1983) |
| "Synergy was also achieved in the T24 bladder cancer line." | 5.31 | Synergistic cytotoxicity and apoptosis of JTE-522, a selective cyclooxygenase-2 inhibitor, and 5-fluorouracil against bladder cancer. ( Kamoi, K; Kawauchi, A; Miki, T; Mizutani, Y; Ukimura, O, 2002) |
| "The objective of the trial is to evaluate the efficacy of capecitabine in patients with metastatic hormone-resistant prostate carcinoma (HRPC), in terms of prostate-specific antigen (PSA) response and clinical benefit (decrease of pain or analgesic score) and its safety profile." | 5.11 | Capecitabine in hormone-resistant metastatic prostatic carcinoma - a phase II trial. ( Bauer, J; Bernhard, J; Bonomo, M; Borner, M; Cerny, T; Dietrich, D; Gillessen, S; Gschwend, A; Hanselmann, S; Hering, F; Morant, R; Rochlitz, C; Schmid, HP; Wernli, M, 2004) |
| "Strontium-89 is an established alternative for the alleviation of bone pain in prostate cancer." | 5.11 | Palliation of bone pain in prostate cancer using chemotherapy and strontium-89. A randomized phase II study. ( Edgren, M; Ginman, C; Kälkner, KM; Nilsson, S; Nordström, B; Ryberg, M; Strang, P; Westlin, JE; Zimmermann, R, 2005) |
| "One hundred forty-two patients with progressive, hormonally refractory advanced prostate carcinoma who had not received prior chemotherapy were randomized to receive either combination chemotherapy with 5-fluorouracil (5-FU), doxorubicin, and mitomycin C (FAM) or sequential chemotherapy with the same agents, i." | 5.07 | Chemotherapy for hormonally refractory advanced prostate carcinoma. A comparison of combined versus sequential treatment with mitomycin C, doxorubicin, and 5-fluorouracil. ( Hahn, RG; Krook, JE; Laurie, JA; Mailliard, JA; Morton, RF; Patel, SR; Therneau, TM; Twito, DI; Windschitl, HE, 1992) |
| "This prospective randomized study in nonhormonally responsive adenocarcinoma of the prostate shows that response rates to melphalan vs cyclophosphamide groups were virtually identical." | 5.06 | Value of cyclophosphamide or melphalan as combined chemotherapy in hormonally unresponsive prostatic carcinoma. ( Berry, WR; Cox, EB; Graham, SD; Laszlo, J; Paulson, DF; Walker, A, 1986) |
| "In patients with metastatic hormone-relapsed adenocarcinoma of the prostate, adriamycin was compared to 5-fluorouracil in a randomized trial in 99 patients and adriamycin alone was studied in an open trial in 48 patients." | 5.05 | A comparative clinical trial of adriamycin and 5-fluorouracil in advanced prostatic cancer: prognostic factors and response. ( Begg, CB; Brodovsky, H; Creech, R; DeWys, WD; Khandekar, J, 1983) |
| "In a prospective, randomized study the effect of cyclophosphamide, methotrexate and 5-fluorouracil combination chemotherapy was compared to the single agent, chloroethyl-cyclohexy-nitrosourea, in the treatment of hormonally refractive metastatic prostatic carcinoma." | 5.05 | Cyclophosphamide, methotrexate and 5-fluorouracil combination chemotherapy versus chloroethyl-cyclohexy-nitrosourea in the treatment of metastatic prostatic cancer. ( Herr, HW, 1982) |
| "This National Cooperative Study has randomly compared the usefulness of 5-fluorouracil (5-FU), cyclophosphamide (Cytoxan) and standard therapy in patients with advanced carcinoma of the prostate (Stage D)." | 5.04 | Prostatic carcinoma. relationship between primary tumor, histologic grade, and response to chemotherapy. ( Gibbons, RP; Johnson, DE; Murphy, GP; Prout, GR; Schmidt, JD; Scott, WW, 1976) |
| "Twenty-seven patients with a diagnosis of metastatic adenocarcinoma of the prostate were treated in a randomized, prospective trial with either Cyclophosphamide or a combination of Adriamycin, 5-Fluorouracil, and Cyclophosphamide." | 5.04 | Cyclophosphamide (NSC 26271) versus the combination of adriamycin (NSC 123127), 5-fluorouracil (NSC 19893), and cyclophosphamide in the treatment of metastatic prostatic cancer: a randomized trial. ( Bateman, JR; Chlebowski, RT; Hestorff, R; Sardoff, L; Weiner, J, 1978) |
| "The national Prostatic Cancer Project has evaluated single and combination chemotherapeutic agents for the treatment of patients with advanced prostatic cancer that has been unresponsive to hormonal therapy." | 3.75 | Chemotherapy of hormonally unresponsive prostatic carcinoma. ( deKernion, JB; Lindner, A, 1984) |
| "Human prostate cancer PC-3 and LnCaP, and human breast cancer MDA-468 cells and xenografts were treated with chemotherapy (docetaxel and 5-fluorouracil, respectively) and temsirolimus, using concurrent and sequential treatment schedules." | 3.75 | Concurrent and sequential administration of chemotherapy and the Mammalian target of rapamycin inhibitor temsirolimus in human cancer cells and xenografts. ( Fung, AS; Tannock, IF; Wu, L, 2009) |
| "In all patients with advanced colorectal cancer, disease eventually progresses following fluorouracil (5-FU) therapy, with a worsening of disease-related symptoms and quality of life (QOL)." | 3.70 | Assessing the impact of chemotherapy on tumor-related symptoms in advanced colorectal cancer. ( Michael, M; Moore, MJ, 1998) |
| "Based upon prior data suggesting that alpha-interferon possesses chemomodulatory activity, the Southwest Oncology Group conducted a study in which patients with hormone refractory, metastatic (stage D2) adenocarcinoma of the prostate were treated with 5-fluorouracil (5-FU) and Roferon-A." | 3.69 | Treatment of stage D2 hormone refractory carcinoma of the prostate with 5-fluorouracil and Roferon-A: a Southwest Oncology Group study. ( Barnett, TC; Crawford, ED; Marshall, ME; O'Rourke, M; Wolf, M, 1996) |
| "We evaluated conventional pulse exposure versus continuous exposure models of 5-fluorouracil (5-FU) radiosensitization in HT-29 (human colon adenocarcinoma) and DU-145 (human prostate cancer adenocarcinoma) cell lines." | 3.68 | 5-Fluorouracil modulation of radiosensitivity in cultured human carcinoma cells. ( Evans, RG; Kimler, BF; Smalley, SR, 1991) |
| "Eleven patients with advanced adenocarcinoma of the prostate were treated with a cyclic alternating chemotherapy (VIP-DMF therapy), consisting of a three-drug combination of vincristine, ifosfamide, and peplomycin; and a three-drug combination of adriamycin, mitomycin C and 5-fluorouracil." | 3.67 | [Alternating combination chemotherapy (VIP-DMF) in patients with advanced adenocarcinoma of the prostate]. ( Akagi, T; Hara, M; Nanba, K; Obama, T; Ochi, J; Ozaki, Y; Saegusa, M; Tanahashi, T; Tsushima, T; Yoshimoto, J, 1987) |
| "Twelve patients with stage D2 adenocarcinoma of the prostate were treated with the combination chemotherapy of ifosfamide (2 g/body, i." | 3.67 | [Combination chemotherapy with ifosfamide, 5-fluorouracil, cisplatin for stage D2 prostatic cancer]. ( Andoh, M; Fukui, I; Higashi, Y; Horiuchi, S; Kihara, K; Kitahara, S; Oshima, H; Takeuchi, S, 1989) |
| "Logothetis and von Eschenbach first 1981 reported encouraging preliminary results of the DMF regimen (Doxorubicine = Adriamycin, Mitomycin, 5 Fluorouracil) in hormone refractory adenocarcinoma of the prostate." | 3.66 | [Treatment of metastasizing prostatic carcinoma with DMF. Presentation of a prospective study]. ( Burk, K; Gropp, C; Rodeck, G, 1983) |
| "Sixty-two patients with metastatic hormonal refractory adenocarcinoma of the prostate received a combination of doxorubicin, mitomycin-C, and 5-fluorouracil (DMF)." | 3.66 | Doxorubicin, mitomycin-C, and 5-fluorouracil (DMF) in the treatment of metastatic hormonal refractory adenocarcinoma of the prostate, with a note on the staging of metastatic prostate cancer. ( Grant, C; Johnson, DE; Logothetis, CJ; Ogden, S; Samuels, ML; Trindade, A; von Eschenbach, AC, 1983) |
| "Twenty-five patients with histologically proved adenocarcinoma of the prostate were divided into two groups and submitted to combination therapy with estramustine (Estracyt), cyclophosphamide (Cytoxan), 5-fluorouracil, and Cisplatin." | 3.66 | Estramustine phosphate with multiple cytotoxic agents in treatment of advanced prostatic cancer. ( Beckley, S; Maeso, E; Murphy, G; Pontes, E; Wajsman, Z, 1981) |
| "Twenty-four patients with confirmed Stage D carcinoma of the prostate were treated with a combination of bilateral orchiectomy, estrogens (diethylstilbestrol) and chemotherapy (5-fluorouracil), and cyclophosphamide soon after diagnosis was established." | 3.66 | Early combined hormonal and chemotherapy for metastatic prostatic carcinoma. ( Lurie, H; Mukamel, E; Nissenkorn, I; Servadio, C, 1983) |
| "A number of chemotherapeutic agents, including L-asparaginase, actinomycin D, chloroethylcyclohexy-nitrosourea, 5-flourouracil, cyclophosphamide, hydroxyurea, cis-platinum, adriamycin and methotrexate, alone and in combination and at variable dose levels, were applied against the Dunning R3327 rat prostatic adenocarcinoma-subline G." | 3.66 | Further experience with chemotherapy in the Dunning prostatic adenocarcinoma. ( Block, NL; Camuzzi, F; Claflin, A; Politano, VA; Stover, B; Troner, M, 1978) |
| "Combination chemotherapy consisting of cyclophosphamide, doxorubicin hydrochloride and 5-fluorouracil was evaluated in 21 patients with metastatic adenocarcinoma of the prostate who were unresponsive to conventional therapy." | 3.66 | Cyclophosphamide, doxorubicin hydrochloride and 5-fluorouracil in advanced carcinoma of the prostate. ( Ikard, M; Shippel, RM; Soloway, MS, 1979) |
| "Arterial infusion of 5-fluorouracil either alone or in combination with supervoltage radiation achieves a definite objective improvement in patients with estrogen-resistant adenocarcinoma of the prostate." | 3.65 | Use of arterial infusion of 5-fluorouracil either alone or in combination with supervoltage radiation as a treatment for carcinoma of the prostate and bladder. ( Hoffman, AA; Nevin, JE, 1975) |
| " The primary end-point was to establish the maximum tolerable dose (MTD) of capecitabine when combined with (188)Re-HEDP." | 2.74 | (188)Re-HEDP combined with capecitabine in hormone-refractory prostate cancer patients with bone metastases: a phase I safety and toxicity study. ( Bosma, TB; Lam, MG; van Rijk, PP; Zonnenberg, BA, 2009) |
| "Capecitabine has limited activity as a single agent in prostate cancer, but appears to modulate tumour biology." | 2.71 | Phase II study of oral capecitabine in patients with hormone-refractory prostate cancer. ( Bolunwu, N; Chan, S; Kendall, A; Pandha, H; Plunkett, T; Somaiah, N; Spicer, J, 2005) |
| "Then, 23 cases of local relapsed prostate cancer and two cases of endpocrine-resistant prostate cancer were administered the chemotherapy." | 2.69 | [Intra-arterial chemotherapy via reservoir system for advanced bladder cancer and prostate cancer]. ( Deguchi, T; Kawada, Y; Kuriyama, M; Nakano, M; Shinoda, I; Takahashi, Y; Takeuchi, T; Yamamoto, N; Yasuda, M; Yoh, M, 1999) |
| "5-Fluorouracil has been reported to have modest antitumor activity in androgen independent prostate cancer." | 2.68 | The results of a phase II randomized trial comparing 5-fluorouracil and 5-fluorouracil plus alpha-interferon: observations on the design of clinical trials for androgen-independent prostate cancer. ( Daliani, DD; Eisenberg, PD; Fueger, R; Logothetis, CJ; Lord, R; Weems, J, 1995) |
| "Hormone-refractory metastatic prostate cancer remains a disease for were limited therapeutic options are available." | 2.68 | [5-Fluorouracil and alpha-2a interferon in patients with hormone-refractory prostate cancer]. ( Demura, T; Harabayashi, T; Koyanagi, T; Matsuda, H; Matsumara, K; Nagomori, S; Nonomura, K; Nounaka, O; Ohmuro, H; Shinohara, N, 1995) |
| "In patients of 70 years and under with prostate cancer resistant to androgen-deprivation therapy and who still have good performance status, ECF chemotherapy can achieve useful remissions." | 2.68 | A phase II study of continuous infusion 5-fluorouracil (5-FU) with epirubicin and cisplatin in metastatic, hormone-resistant prostate cancer: an active new regimen. ( Chao, D; Harland, SJ; von Schlippe, M, 1997) |
| "5-fluorouracil (5-FU) is a known radiosensitizer that enhances efficacy, in vivo and in vitro, when administered during radiotherapy." | 2.68 | Brachytherapy and continuous infusion 5-fluorouracil for treatment of locally advanced, lymph node negative, prostate cancer: a phase I trial. ( Dreicer, R; Forest, PK; Loening, S; See, WA; Wheeler, JA, 1996) |
| "2 per day) combined with a fixed dose of interferon-alpha 2b (5 million units) and allopurinol (300 mg." | 2.68 | 5-fluorouracil and allopurinol combined with recombinant interferon-alpha 2b in the treatment of patients with advanced prostate cancer: a phase I/II study. ( Amdur, RJ; Ernstoff, MS; Fukui, I; Glazier, DB; Harris, R; Heaney, JA; Schned, AR, 1996) |
| " 5FU was given as a 24-hour infusion at a dosage of 4 g/m2 and oral leucovorin at a dosage of 50 mg every 6 hours for four doses, starting with the infusion of 5FU." | 2.68 | Leucovorin and high-dose fluorouracil in metastatic prostate cancer. A phase II trial of the piedmont Oncology Association. ( Atkins, JN; Case, LD; Grote, T; McFarland, J; Muss, HB; Richards, F, 1996) |
| " Patients were treated with 5-fluorouracil given at a dosage of 4 gm/m2 over a 24-hour period every 2 weeks." | 2.67 | High-dose 24-hour infusion of 5-fluorouracil in metastatic prostate cancer. A phase II trial of the Piedmont Oncology Association. ( Anthony, S; Atkins, JN; Brockschmidt, J; Case, D; Grote, TH; Muss, HB; O'Rourke, M; Schnell, FM; Stanley, V; West, JH, 1991) |
| " Frequent dosage modifications were required with the dose intensity of 5-FU and alpha interferon of 57% and 58%, respectively." | 2.67 | Phase II trial of 5-fluorouracil and alpha-2b interferon in patients with hormone-refractory metastatic prostate cancer. ( Dreicer, R; Forest, PK; Williams, RD, 1994) |
| "5-Fluorouracil (5-FU) has been previously associated with therapeutic benefit in hormone refractory prostate cancer." | 2.67 | A phase II study of continuous infusion 5-fluorouracil in advanced hormone refractory prostate cancer. An Illinois Cancer Center Study. ( Benson, AB; Blough, R; Braud, E; Johnson, P; Kilton, L; Kozlowski, J; Kuzel, TM; Shevrin, D; Tallman, MS; Vogelzang, NJ, 1993) |
| "Hormone-refractory metastatic prostate cancer remains a therapeutic challenge." | 2.67 | Cyclophosphamide, methotrexate, and 5-fluorouracil in the treatment of metastatic prostate cancer. A Southwest Oncology Group study. ( Blumenstein, BA; Boileau, M; Crawford, ED; Fletcher, WS; Rivkin, SE; Wozniak, AJ, 1993) |
| "Twenty patients with metastatic prostatic cancer were treated on an ambulatory basis with continuous 5-fluorouracil (5-FU) infusion 250-300 mg/M2 per day through a chronic indwelling central venous catheter." | 2.67 | Continuous systemic 5-fluorouracil infusion in refractory prostatic cancer. ( Anderson, T; Beatty, P; Hansen, R; Libnoch, J; Moynihan, T; Quebbeman, E; Schulte, W, 1991) |
| "Seventy-five patients with stage D-2 prostate cancer refractory to orchiectomy have been entered in a controlled trial to test whether androgen priming enhances the efficacy of chemotherapy." | 2.66 | Androgen depletion and repletion as a means of potentiating the effect of cytotoxic chemotherapy in advanced prostate cancer. ( Boucher, AE; Drago, J; Gordon, R; Harvey, H; Lipton, A; Manni, A; Rohner, T; Santen, RJ; Simmonds, M; Wettlaufer, J, 1987) |
| "Eighty-five men with progressive prostate cancer refractory to orchiectomy were treated continuously with aminoglutethimide and hydrocortisone to lower adrenal androgen secretion and were administered cyclic intravenous (IV) chemotherapy." | 2.66 | Androgen priming and chemotherapy in advanced prostate cancer: evaluation of determinants of clinical outcome. ( Bartholomew, M; Boucher, A; Caplan, R; Gordon, R; Harvey, H; Lipton, A; Manni, A; Santen, R; Simmonds, M; White-Hershey, D, 1988) |
| " Future studies utilizing these or other agents, in similar or modified dosage schedules or delivery mechanisms, should note these results." | 2.66 | Hormone-refractory metastatic prostatic cancer treated with methotrexate, cyclophosphamide plus adriamycin, cis-platinum plus 5-fluorouracil plus cyclophosphamide. National Prostatic Cancer Project randomized trial. ( Murphy, GP; Priore, RL; Scardino, PT, 1988) |
| "Although patients with metastatic prostatic cancer may benefit from chemotherapy, impressive clinical responses are uncommon." | 2.65 | Cyclophosphamide versus cyclophosphamide, methotrexate, and 5-fluorouracil in advanced prostatic cancer: a randomized trial. ( Brodkin, R; Cooper, MR; Howard, V; Jackson, DV; Muss, HB; Resnick, MI; Richards, F; Spurr, CL; Stuart, JJ; White, DR, 1981) |
| "The Southeastern Cancer Study Group has evaluated 5-fluorouracil administered intravenously weekly at a dosage of 600 mg." | 2.65 | A phase II evaluation of a 3-drug combination of cyclophosphamide, doxorubicin and 5-fluorouracil and of 5-fluorouracil in patients with advanced bladder carcinoma or stage D prostatic carcinoma. ( Bartolucci, AA; Hemstreet, G; Hester, M; Smalley, RV, 1981) |
| " Effectiveness of 5-fluorouracil in combination with hormones (estrogen or gestagen) in low doses, as a basal treatment, was compared with that of hormones alone in high doses." | 2.65 | [Effectiveness of 5-fluorouracil combined with hormones in low dose as a basal treatment for prostatic carcinoma]. ( Takeuchi, H, 1984) |
| "The National Prostatic Cancer Project has randomized this study for endocrine-resistant prostatic cancer patients for treatment with standard hormonal or other therapies compared to 5-fluorouracil and cyclophosphamide." | 2.64 | Chemotherapy of advanced prostatic carcinoma with cyclophosphamide or 5-fluorouracil: results of first national randomized study. ( Gibbons, RP; Johnson, DE; Joiner, JR; Murphy, GP; Prout, GR; Saroff, J; Schmidt, JE; Scott, WW, 1975) |
| " While clinical efficacy was limited with the viral mutants alone, outcomes were improved in combination with chemotherapeutics." | 2.45 | Optimisation of replication-selective oncolytic adenoviral mutants in combination with chemotherapeutics. ( Halldén, G, 2009) |
| "The efficacy of chemotherapy for prostatic cancer is difficult to evaluate owing to the low incidence of measurable indicator lesions and the resulting need for indirect response criteria." | 2.37 | Chemotherapy principles in the treatment of prostatic cancer. ( Könyves, I; Müntzing, J; Rozencweig, M, 1984) |
| "Alopecia was observed in 60% of patients." | 1.62 | Toxicity profile of taxanes in Tunisian cancer patients: A retrospective study of 90 cases. ( Ayari, J; Balti, M; Ben Abdallah, I; Ben Hassen, M; Ben Nasr, S; Doghri, Y; Fendri, S; Haddaoui, A; Trigui, E; Zribi, A, 2021) |
| " These results also validate that CLZ has significant anticancer activity both alone and in combination and support the strategy of drug repurposing coupled to drug combination for prostate cancer therapy." | 1.62 | Synergistic Interaction of CPP2 Coupled with Thiazole Derivates Combined with Clotrimazole and Antineoplastic Drugs in Prostate and Colon Cancer Cell Lines. ( Duarte, D; Vale, N, 2021) |
| "We report the case of an 84 years old prostate cancer patient with severe side effects after radiotherapy in 2006." | 1.39 | Persisting ring chromosomes detected by mFISH in lymphocytes of a cancer patient-a case report. ( Eble, MJ; Kriehuber, R; Pinkawa, M; Schmitz, S, 2013) |
| "LNCaP cells, androgen dependent prostate cancer (ADPC) cells and C4-2 cells, which are a CRPC subline of LNCaP cells, were used." | 1.38 | Low-dose docetaxel enhances the sensitivity of S-1 in a xenograft model of human castration resistant prostate cancer. ( Hasegawa, M; Ide, H; Kikuchi, E; Kosaka, T; Maeda, T; Miyajima, A; Oya, M; Shirotake, S; Tanaka, N; Yasumizu, Y, 2012) |
| "The risk of prostate cancer has been increasing in men by degrees." | 1.38 | Effects of genetically engineered stem cells expressing cytosine deaminase and interferon-beta or carboxyl esterase on the growth of LNCaP rrostate cancer cells. ( Choi, KC; Hwang, KA; Kim, SU; Kim, YB; Yi, BR, 2012) |
| "HCT116 colorectal or PPC1 prostate cancer cells were treated with quercetin and the drugs." | 1.38 | Dual-mode interaction between quercetin and DNA-damaging drugs in cancer cells. ( Fadlalla, K; Katkoori, V; Manne, U; Mosley, L; Samuel, T; Turner, T, 2012) |
| "Among the panel of cancer cell lines, all studied polymeric FdU-conjugates demonstrated an up to 50× increased cytotoxicity in human prostate cancer PC-3, breast cancer MCF-7, and MDA-MB-231 cells, and more than 100× higher efficacy against cytarabine-resistant human T-lymphoma (CEM/araC/8) and gemcitabine-resistant follicular lymphoma (RL7/G) cells as compared to free drugs." | 1.37 | Novel anticancer polymeric conjugates of activated nucleoside analogues. ( Senanayake, TH; Vinogradov, SV; Warren, G, 2011) |
| "Some prostate and breast cancer cell lines highly expressed NCAM2 whereas normal prostate cell lines expressed NCAM2 at low levels." | 1.37 | Neural cell adhesion molecule 2 as a target molecule for prostate and breast cancer gene therapy. ( Hamada, H; Kato, K; Kubota, K; Nakamura, K; Nakano, R; Takahashi, S, 2011) |
| " These results suggest that the up-regulation of IGFBP3 induced by 5-FU plays an important role in the potent anti-tumor effect of 5-FU combined with anti-androgens on CRPC." | 1.37 | Up-regulation of insulin-like growth factor-binding protein 3 by 5-fluorouracil (5-FU) leads to the potent anti-proliferative effect of androgen deprivation therapy combined with 5-FU in human prostate cancer cell lines. ( Itoh, K; Kanayama, H; Kawabata, R; Oie, S; Oka, T; Takahashi, M, 2011) |
| "Twenty men with primary rectal cancer clinically involving the lower urinary tract organs underwent extended colorectal resection combined with radical prostatectomy." | 1.36 | Preliminary experience with bladder preservation for lower rectal cancers involving the lower urinary tract. ( Ito, M; Kobayashi, A; Minagawa, N; Nishizawa, Y; Saito, N; Sugito, M; Suzuki, T; Tanaka, T; Watanabe, K, 2010) |
| "The various percentages of prostate cancer cells (LNCaP) transfected and non-transfected were mixed to observe the bystander effect of suicide gene system UPRT/5-FU." | 1.35 | [Bystander effect of target-regulated uracil phosphoribosyltransferase/5-fluorouracil suicide gene system on prostate cancer cell]. ( Li, H; Li, X; Wei, Q; Zeng, H; Zhao, FJ, 2008) |
| "Taking advantage of this prostate cancer-specific property of PSMA(E/P), we successfully introduced bacterial UPRT into LNCaP cells where the tumoricidal effect of 5-fluorouracil (5-FU) was significantly increased when compared with the cells without the exogenous UPRT." | 1.35 | Specific targeting of prostate cancer cells in vitro by the suicide gene/prodrug system, uracil phosphoribosyltransferase/5-fluorouracil, under the control of prostate-specific membrane antigen promoter/enhancer. ( Li, H; Xia, SJ; Yu, ZM; Zhang, S; Zhao, FJ, 2009) |
| "Fourteen human cancer cell lines with and without DNA MMR derived from carcinomas of the colon, bladder, ovary and prostate were treated with CAI, vehicle or control drugs (nifedipine and 5-flurouracil)." | 1.35 | Selective sensitivity to carboxyamidotriazole by human tumor cell lines with DNA mismatch repair deficiency. ( Friedlander, ML; Kohn, EC; Qu, XJ; Yang, JL; Yu, Y, 2008) |
| "Although patients with metastatic prostate cancer can benefit from androgen ablation, most of them will die of prostate cancer progression to an androgen-refractory state." | 1.34 | Bevacizumab plus 5-fluorouracil induce growth suppression in the CWR-22 and CWR-22R prostate cancer xenografts. ( Hung, H, 2007) |
| "He was diagnosed as advanced sigmoid colon cancer which invaded the rectal colon (Ra) and prostate (SI, N 0, P 0, H 0, M (-), cStage IIIa)." | 1.34 | [A case of advanced colon cancer invading the rectum effectively treated with chemoradiation therapy before surgery]. ( Maezawa, K; Mizukami, H; Nemoto, H; Sanada, Y; Sasaya, S; Yoshizawa, Y, 2007) |
| "We herein report on a case of pure squamous cell carcinoma of the prostate approached with combined-modality treatment, with the administration of 3 courses of cisplatin 75 mg/m(2) on day 1 and continuous infusion 5-fluorouracil 750 mg/m2 on day 1 to 5 and, subsequently, radiotherapy, with the delivery of a total dose of 46 Gy to the whole pelvis, with additional boost doses of 20 Gy to the prostatic bed and adjunctive 6 Gy to the prostate gland (72 Gy in total)." | 1.34 | Squamous cell carcinoma of the prostate: long-term survival after combined chemo-radiation. ( Ciammella, P; Clerico, M; Filippi, AR; Franco, P; Giudici, M; Munoz, F; Ricardi, U, 2007) |
| "In cultured human prostate cancer lines (DU145 and LNCaP), we compared the cytotoxicity of 5-FU/CDHP with that of 5-FU alone." | 1.34 | The significance of the expression of dihydropyrimidine dehydrogenase in prostate cancer. ( Kawauchi, A; Li, Y; Mikami, K; Miki, T; Mizutani, Y; Nakamura, T; Okihara, K; Sakai, T; Shiraishi, T; Takaha, N, 2007) |
| "With these fluorescent tools, tumors and metastasis in host organs can be externally imaged down to the single-cell level." | 1.33 | Orthotopic metastatic (MetaMouse) models for discovery and development of novel chemotherapy. ( Hoffman, RM, 2005) |
| "Eligible patients had prostate cancer with clinical evidence of invasion through the prostatic capsule or into the seminal vesicles without evidence of nodal or distant metastasis." | 1.33 | Locally advanced prostate cancer treated with concomitant radiation and 5-fluorouracil: Southwest Oncology Group Study 9024. ( Crawford, ED; Faulkner, J; Noble, MJ; O'Rourke, TJ; Quick, DP; Smalley, SR; Stephens, RL; Swanson, GP; Thompson, IM; Weiss, GR, 2006) |
| "Limitations of prostate cancer therapy may be overcome by combinations of chemotherapeutic agents with gene therapy directed against specific proteins critical for disease progression." | 1.33 | Therapeutic interactions between stathmin inhibition and chemotherapeutic agents in prostate cancer. ( Atweh, GF; Mistry, SJ, 2006) |
| " These can be enhanced with ultrasound imaging that depicts tumor margins; facilitates guidance, delivery, and dosage of local chemotherapy; and can monitor the effectiveness of the treatment." | 1.32 | Ultrasound guided combined cryoablation and microencapsulated 5-Fluorouracil inhibits growth of human prostate tumors in xenogenic mouse model assessed by luminescence imaging. ( Aller, A; Doulat, J; Haddad, RS; Le Pivert, P; Morrison, DR; Renard, M; Titus, K, 2004) |
| "Bioluminescent PC-3M-luc-C6 human prostate cancer cells were implanted subcutaneously into SCID-beige mice and were monitored for tumor growth and response to 5-FU and mitomycin C treatments." | 1.32 | Bioluminescent imaging (BLI) to improve and refine traditional murine models of tumor growth and metastasis. ( Contag, PR; Dusich, J; Hornig, YS; Jenkins, DE; Oei, Y; Purchio, T; Yu, SF, 2003) |
| "5-Fluorouracil is known to inhibit thymidylate synthase (TS), a key enzyme that transfers a methyl group from 5,10-methylene-tetrahydrofolate to dUMP during nucleotide biosynthesis." | 1.32 | Methionine restriction selectively targets thymidylate synthase in prostate cancer cells. ( Chen, GL; Epner, DE; Kwabi-Addo, B; Lu, S; Ren, C, 2003) |
| "A survey of cancer treatment in a sample of hospitals > 100 beds conducted in 1998 compared with experience in the US showed that good progress has been achieved in Japan in the screening and early treatment of gastric cancer, and that the prognosis for breast cancer is better than in the West." | 1.31 | [Development of molecular targeting drugs for the treatment of cancer-therapeutic potential and issues to be addressed in global development]. ( Aiba, K; Akaza, H; Blackledge, G; Hinotsu, S; Isonishi, S; Kono, S; Mikami, O; Noguchi, S; Ogawa, O; Shibuya, M; Sone, S; Stribling, D; Tsuruo, T; Vose, B, 2000) |
| "Two patients were diagnosed with large rectal tumors and localized prostate cancer." | 1.31 | External beam radiotherapy for synchronous rectal and prostatic tumors. ( Kapp, DS; King, C; Siu, W; Terris, MK; Wren, SM, 2001) |
| "A human prostate cancer cell (PC-3) model was exposed to 5-fluorouracil (5-FU) for 2 and 4 days (prefreeze), freezing (-5 to -100 degrees C), or a combination of the two treatments, and each was assessed for effectiveness over a 2-week posttreatment period." | 1.31 | Chemo-cryo combination therapy: an adjunctive model for the treatment of prostate cancer. ( Baust, JG; Baust, JM; Clarke, DM; Van Buskirk, RG, 2001) |
| "Carmustine (BCNU) is an anticancer agent and a putative inhibitor of Gly-I, while beta-glucan is a unique, nontoxic polysaccharide extracted from maitake mushrooms." | 1.31 | Chemosensitization of carmustine with maitake beta-glucan on androgen-independent prostatic cancer cells: involvement of glyoxalase I. ( Aynehchi, S; Choudhury, MS; Drinis, S; Finkelstein, MP; Konno, S; Samadi, AA; Tazaki, H, 2002) |
| "LNCaP human prostate cancer cells were co-transfected with these 2 plasmids and luciferase activity was measured to assess promoter activities." | 1.31 | Adenovirus mediated prostate specific enzyme prodrug gene therapy using prostate specific antigen promoter enhanced by the Cre-loxP system. ( Hayakawa, M; Ikegami, S; Suzuki, S; Tadakuma, T; Yoshimura, I, 2002) |
| "Synergy was also achieved in the T24 bladder cancer line." | 1.31 | Synergistic cytotoxicity and apoptosis of JTE-522, a selective cyclooxygenase-2 inhibitor, and 5-fluorouracil against bladder cancer. ( Kamoi, K; Kawauchi, A; Miki, T; Mizutani, Y; Ukimura, O, 2002) |
| "Then, 23 cases with local relapsed prostate cancer and two cases with endocrine-resistant prostate cancer received chemotherapy." | 1.30 | [Intraarterial chemotherapy via reservoir system for far-advanced bladder and prostate cancer]. ( Deguchi, T; Kawada, Y; Kuriyama, M; Nakano, M; Shinoda, I; Takahashi, Y; Takeuchi, T; Yamamoto, N; Yasuda, M; Yoh, M, 1998) |
| "The protocol for renal cell carcinoma consisted of combined chemotherapy with continuous infusion of 5-FU 250 mg/m2/day and CDDP 3 mg/m2/day in 2 weeks for 1 cycles (4 weeks)." | 1.30 | [Outpatient chemotherapy with continuous intravenous infusion for patients with recurrent renal cell carcinoma or advanced prostate carcinoma]. ( Hata, M; Ono, S; Ota, N; Otsuka, A, 1997) |
| "Suramin has shown antitumour activity in vitro and in vivo." | 1.29 | The synergistic and antagonistic effects of cytotoxic and biological agents on the in vitro antitumour effects of suramin. ( Lopez Lopez, R; Peters, GJ; Pinedo, HM; van Rijswijk, RE; Wagstaff, J, 1994) |
| "Forty-one patients with bladder cancer and 12 patients with prostatic cancer were evaluated." | 1.28 | [Phase II study of 5'-DFUR treatment of the bladder and prostatic cancer]. ( Akebi, N; Josen, T; Kobashi, K; Matsumura, Y; Nanba, K; Nasu, Y; Ochi, J; Ohmori, H; Saika, T; Tanahashi, T, 1991) |
| " These data suggest that differentiation agents may provide additional antineoplastic benefits when administered in combination with selected chemotherapeutic agents in the management of prostatic cancer." | 1.28 | Conventional chemotherapeutic agents combined with DMSO or DFMO in treatment of rat prostate carcinoma. ( Carvalho, L; Foulkes, K; Mickey, DD, 1989) |
| "A human testicular cancer serially transplanted in nude mice was repeatedly exposed to CDDP in vivo to obtain hyposensitivity to this drug." | 1.27 | [Chemotherapy of carcinoma of the prostate and testis: experimental study in vivo and in vitro]. ( Hashimura, T; Hida, S; Kanamaru, H; Nishimura, K; Nishio, Y; Oishi, K; Okada, K; Yamauchi, T; Yoshida, O; Yoshiki, T, 1988) |
| "The 5-FU concentration of prostatic cancer was almost equal to that of normal prostatic tissue." | 1.27 | [Study on the concentration of FT-207 and 5-FU in serum and tissues of bladder tumor and prostatic carcinoma]. ( Kobayashi, H; Obata, K; Sahashi, M, 1986) |
| "Regional arterial infusion of high doses of anti-cancer drugs combined with direct hemoperfusion was done in 12 patients with malignancies of the urinary tract." | 1.26 | Efficacy and side effects of the regional arterial infusion of anti-cancer drugs combined with direct hemoperfusion in malignancies of the urinary tract. ( Harada, T; Nishizawa, O; Ohmura, H; Tsuchida, S, 1982) |
| "Hepatic hypoglycemia is discussed and the literature is reviewed." | 1.26 | Hypoglycemia secondary to metastases to the liver. A case report and review of the literature. ( Chawla, SK; LoPresti, PA; Sossi, AJ; Soterakis, J; Younus, S, 1977) |
| "A trial to reduce the dosage of estrogen or to substitute it by other agents was done as a treatment of prostatic carcinoma." | 1.26 | The therapeutic effect of concurrent administration of 5-fluorouracil and allylestrenol or hexestrol in small doses on prostatic carcinoma. ( Takeuchi, H, 1981) |
| "The problems of defining response in prostatic cancer are discussed and a protocol for the future is outlined." | 1.26 | The non-hormone chemotherapy of prostatic cancer. ( Jones, MA; Williams, G, 1980) |
| "A significant decrease in the number of metastases was observed in the triple drug therapy, administered for three cycles, BCNU only, and BCNU and adriamycin." | 1.26 | Triple drug chemotherapy in treatment of prostate adenocarcinoma Nb Pr A.I.-III. ( Drago, JR; Worgul, TJ, 1981) |
| "Soft tissue metastases may be more responsive than bony lesions." | 1.26 | Chemotherapy trial with comp-F regimen in advanced adenocarcinoma of prostate. ( Bergreen, PW; Buell, GV; Saiers, JH; Saiki, JH, 1978) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 125 (44.64) | 18.7374 |
| 1990's | 43 (15.36) | 18.2507 |
| 2000's | 67 (23.93) | 29.6817 |
| 2010's | 40 (14.29) | 24.3611 |
| 2020's | 5 (1.79) | 2.80 |
| Authors | Studies |
|---|---|
| Gududuru, V | 4 |
| Hurh, E | 4 |
| Durgam, GG | 1 |
| Hong, SS | 1 |
| Sardar, VM | 1 |
| Xu, H | 1 |
| Dalton, JT | 4 |
| Miller, DD | 4 |
| Sullivan, J | 1 |
| Liu, XH | 1 |
| Lv, PC | 1 |
| Xue, JY | 1 |
| Song, BA | 1 |
| Zhu, HL | 1 |
| Reddy, DM | 1 |
| Qazi, NA | 1 |
| Sawant, SD | 1 |
| Bandey, AH | 1 |
| Srinivas, J | 1 |
| Shankar, M | 1 |
| Singh, SK | 1 |
| Verma, M | 1 |
| Chashoo, G | 1 |
| Saxena, A | 1 |
| Mondhe, D | 1 |
| Saxena, AK | 1 |
| Sethi, VK | 1 |
| Taneja, SC | 1 |
| Qazi, GN | 1 |
| Sampath Kumar, HM | 1 |
| Riganas, S | 1 |
| Papanastasiou, I | 1 |
| Foscolos, GB | 1 |
| Tsotinis, A | 1 |
| Serin, G | 1 |
| Mirjolet, JF | 1 |
| Dimas, K | 1 |
| Kourafalos, VN | 1 |
| Eleutheriades, A | 1 |
| Moutsos, VI | 1 |
| Khan, H | 2 |
| Georgakopoulou, S | 1 |
| Zaniou, A | 1 |
| Prassa, M | 1 |
| Theodoropoulou, M | 1 |
| Mantelas, A | 1 |
| Pondiki, S | 1 |
| Vamvakides, A | 1 |
| Liu, GZ | 1 |
| Xu, HW | 1 |
| Wang, P | 1 |
| Lin, ZT | 1 |
| Duan, YC | 1 |
| Zheng, JX | 1 |
| Liu, HM | 1 |
| Mochona, B | 1 |
| Qi, X | 1 |
| Euynni, S | 1 |
| Sikazwi, D | 1 |
| Mateeva, N | 1 |
| Soliman, KF | 1 |
| Sun, CP | 1 |
| Qiu, CY | 1 |
| Yuan, T | 1 |
| Nie, XF | 1 |
| Sun, HX | 1 |
| Zhang, Q | 1 |
| Li, HX | 1 |
| Ding, LQ | 1 |
| Zhao, F | 1 |
| Chen, LX | 1 |
| Qiu, F | 1 |
| Mandalapu, D | 1 |
| Saini, KS | 1 |
| Gupta, S | 1 |
| Sharma, V | 1 |
| Yaseen Malik, M | 1 |
| Chaturvedi, S | 1 |
| Bala, V | 1 |
| Thakur, S | 1 |
| Maikhuri, JP | 1 |
| Wahajuddin, M | 1 |
| Konwar, R | 1 |
| Gupta, G | 1 |
| Sharma, VL | 1 |
| Cao, Y | 1 |
| Yang, Y | 3 |
| Ampomah-Wireko, M | 1 |
| Obaid Arhema Frejat, F | 1 |
| Zhai, H | 1 |
| Zhang, S | 2 |
| Wang, H | 3 |
| Yang, P | 1 |
| Yuan, Q | 1 |
| Wu, G | 1 |
| Wu, C | 2 |
| Dung, DTM | 1 |
| Park, EJ | 1 |
| Anh, DT | 1 |
| Hai, PT | 1 |
| Huy, LD | 1 |
| Jun, HW | 1 |
| Kwon, JH | 1 |
| Young Ji, A | 1 |
| Kang, JS | 1 |
| Tung, TT | 1 |
| Dung, PTP | 1 |
| Han, SB | 1 |
| Nam, NH | 1 |
| Duarte, D | 1 |
| Vale, N | 1 |
| Salerno, L | 1 |
| Sorrenti, V | 1 |
| Pittalà, V | 1 |
| Consoli, V | 1 |
| Modica, MN | 1 |
| Romeo, G | 1 |
| Marrazzo, A | 1 |
| Giuliano, M | 1 |
| Zajdel, P | 1 |
| Vanella, L | 1 |
| Intagliata, S | 1 |
| Fukui, K | 1 |
| Nagasawa, S | 1 |
| Hanasaki, T | 1 |
| Ueda, Y | 1 |
| Aihara, K | 1 |
| Kokura, K | 1 |
| Matsuo, S | 1 |
| Zozumi, M | 1 |
| Tsukamoto, Y | 1 |
| Ben Nasr, S | 1 |
| Zribi, A | 1 |
| Ben Hassen, M | 1 |
| Doghri, Y | 1 |
| Ben Abdallah, I | 1 |
| Trigui, E | 1 |
| Fendri, S | 1 |
| Ayari, J | 1 |
| Balti, M | 1 |
| Haddaoui, A | 1 |
| Denslow, A | 1 |
| Świtalska, M | 1 |
| Jarosz, J | 1 |
| Papiernik, D | 1 |
| Porshneva, K | 1 |
| Nowak, M | 1 |
| Wietrzyk, J | 1 |
| Schmitz, S | 1 |
| Pinkawa, M | 1 |
| Eble, MJ | 1 |
| Kriehuber, R | 1 |
| Dueregger, A | 1 |
| Guggenberger, F | 1 |
| Barthelmes, J | 1 |
| Stecher, G | 1 |
| Schuh, M | 1 |
| Intelmann, D | 1 |
| Abel, G | 1 |
| Haunschild, J | 1 |
| Klocker, H | 1 |
| Ramoner, R | 1 |
| Sampson, N | 1 |
| Bazan, JG | 1 |
| Luxton, G | 1 |
| Kozak, MM | 1 |
| Anderson, EM | 1 |
| Hancock, SL | 1 |
| Kapp, DS | 2 |
| Kidd, EA | 1 |
| Koong, AC | 1 |
| Chang, DT | 1 |
| Jin, P | 1 |
| Xie, J | 1 |
| Zhu, X | 3 |
| Zhou, C | 1 |
| Ding, X | 1 |
| Yang, L | 1 |
| Carmona, R | 1 |
| Pritz, J | 1 |
| Bydder, M | 1 |
| Gulaya, S | 1 |
| Zhu, H | 1 |
| Williamson, CW | 1 |
| Welch, CS | 1 |
| Vaida, F | 1 |
| Bydder, G | 1 |
| Mell, LK | 1 |
| Hajikarimi, Z | 1 |
| Khoei, S | 1 |
| Khoee, S | 1 |
| Mahdavi, SR | 1 |
| Yang, Q | 1 |
| Li, L | 1 |
| Sun, W | 1 |
| Huang, Y | 2 |
| Zhang, L | 1 |
| Hoffman, RM | 2 |
| Deng, Y | 1 |
| Wang, J | 2 |
| Zhao, FJ | 2 |
| Li, H | 2 |
| Zeng, H | 1 |
| Wei, Q | 1 |
| Li, X | 1 |
| Yu, ZM | 1 |
| Xia, SJ | 1 |
| Tanaka, T | 4 |
| Kawashima, H | 2 |
| Matsumura, K | 2 |
| Yamashita-Hosono, T | 1 |
| Yoshimura, R | 1 |
| Kuratsukuri, K | 2 |
| Harimoto, K | 1 |
| Nakatani, T | 3 |
| Iguchi, T | 1 |
| Uchida, J | 1 |
| Nakamura, T | 2 |
| Kawamura, M | 1 |
| Wakasa, K | 1 |
| Zheng, C | 1 |
| Ren, Z | 1 |
| Zhang, W | 1 |
| Kalvakolanu, DV | 1 |
| Tian, Z | 1 |
| Xiao, W | 1 |
| Lam, MG | 1 |
| Bosma, TB | 1 |
| van Rijk, PP | 1 |
| Zonnenberg, BA | 1 |
| Xing, L | 1 |
| Sun, X | 1 |
| Deng, X | 1 |
| Kotedia, K | 1 |
| Urano, M | 1 |
| Koutcher, JA | 1 |
| Ling, CC | 1 |
| Li, GC | 1 |
| Le Pivert, PJ | 1 |
| Morrison, DR | 2 |
| Haddad, RS | 2 |
| Renard, M | 2 |
| Aller, A | 2 |
| Titus, K | 2 |
| Doulat, J | 2 |
| Vaishampayan, UN | 1 |
| Marur, S | 1 |
| Heilbrun, LK | 1 |
| Cher, ML | 1 |
| Dickow, B | 1 |
| Smith, DW | 1 |
| Al Hasan, SA | 1 |
| Eliason, J | 1 |
| Fung, AS | 1 |
| Wu, L | 1 |
| Tannock, IF | 1 |
| Waller, EK | 1 |
| Barlett, N | 1 |
| Chen, CH | 1 |
| Mujic, V | 1 |
| Sussman, H | 1 |
| Toepker, S | 1 |
| Grenier, K | 1 |
| Halldén, G | 1 |
| Mishra, PK | 1 |
| Gulbake, A | 1 |
| Jain, A | 1 |
| Vyas, SP | 1 |
| Jain, SK | 1 |
| Cavarretta, IT | 1 |
| Altanerova, V | 1 |
| Matuskova, M | 1 |
| Kucerova, L | 1 |
| Culig, Z | 1 |
| Altaner, C | 1 |
| Njiaju, UO | 1 |
| Truica, CI | 1 |
| Rousseau, F | 1 |
| Retornaz, F | 1 |
| Joly, F | 1 |
| Esterni, B | 1 |
| Abadie-Lacourtoisie, S | 1 |
| Fargeot, P | 3 |
| Luporsi, E | 1 |
| Servent, V | 1 |
| Laguerre, B | 1 |
| Brain, E | 1 |
| Geneve, J | 1 |
| Wang, BD | 1 |
| Kline, CL | 1 |
| Pastor, DM | 1 |
| Olson, TL | 1 |
| Frank, B | 1 |
| Luu, T | 1 |
| Sharma, AK | 1 |
| Robertson, G | 1 |
| Weirauch, MT | 1 |
| Patierno, SR | 1 |
| Stuart, JM | 1 |
| Irby, RB | 1 |
| Lee, NH | 1 |
| Walter, B | 1 |
| Rogenhofer, S | 1 |
| Vogelhuber, M | 1 |
| Berand, A | 1 |
| Wieland, WF | 1 |
| Andreesen, R | 1 |
| Reichle, A | 2 |
| Gasent Blesa, JM | 1 |
| Giner Marco, V | 1 |
| Giner-Bosch, V | 1 |
| Cerezuela Fuentes, P | 1 |
| Alberola Candel, V | 1 |
| Saito, N | 1 |
| Suzuki, T | 1 |
| Sugito, M | 1 |
| Ito, M | 1 |
| Kobayashi, A | 1 |
| Nishizawa, Y | 2 |
| Minagawa, N | 1 |
| Watanabe, K | 1 |
| Takahashi, S | 1 |
| Kato, K | 1 |
| Nakamura, K | 1 |
| Nakano, R | 1 |
| Kubota, K | 1 |
| Hamada, H | 2 |
| Kawabata, R | 2 |
| Oie, S | 2 |
| Oka, T | 2 |
| Takahashi, M | 2 |
| Kanayama, H | 2 |
| Itoh, K | 2 |
| Hasegawa, M | 1 |
| Miyajima, A | 1 |
| Kosaka, T | 1 |
| Yasumizu, Y | 1 |
| Tanaka, N | 1 |
| Maeda, T | 1 |
| Shirotake, S | 1 |
| Ide, H | 1 |
| Kikuchi, E | 1 |
| Oya, M | 1 |
| Paumier, A | 1 |
| Le Péchoux, C | 1 |
| Nishihara, C | 1 |
| Senanayake, TH | 1 |
| Warren, G | 1 |
| Vinogradov, SV | 1 |
| Simon, M | 1 |
| Bioulac-Sage, P | 1 |
| Trillaud, H | 1 |
| Blanc, JF | 1 |
| Ben-Josef, E | 1 |
| Lawrence, TS | 1 |
| Meng, LJ | 1 |
| Fan, WF | 1 |
| Pu, XL | 1 |
| Liu, FY | 1 |
| Yang, M | 1 |
| Zhou, Z | 1 |
| He, S | 1 |
| Fan, T | 1 |
| Jin, Y | 1 |
| Chen, C | 1 |
| Zhang, ZR | 1 |
| Samuel, T | 1 |
| Fadlalla, K | 1 |
| Mosley, L | 1 |
| Katkoori, V | 1 |
| Turner, T | 1 |
| Manne, U | 1 |
| Roldán, AM | 1 |
| Núñez, NF | 1 |
| Grande, E | 1 |
| García, AÁ | 1 |
| Antón-Aparicio, LM | 1 |
| Nagashima, T | 1 |
| Niiro, M | 1 |
| Hirayama, K | 1 |
| Date, S | 1 |
| Okihara, K | 2 |
| Mukaisho, K | 1 |
| Yi, BR | 1 |
| Hwang, KA | 1 |
| Kim, YB | 1 |
| Kim, SU | 1 |
| Choi, KC | 1 |
| Corban-Wilhelm, H | 2 |
| Hull, WE | 1 |
| Becker, G | 2 |
| Bauder-Wüst, U | 2 |
| Greulich, D | 2 |
| Debus, J | 2 |
| Mizutani, Y | 2 |
| Kamoi, K | 1 |
| Ukimura, O | 1 |
| Kawauchi, A | 2 |
| Miki, T | 2 |
| Yoshimura, I | 1 |
| Ikegami, S | 2 |
| Suzuki, S | 1 |
| Tadakuma, T | 1 |
| Hayakawa, M | 1 |
| Bex, A | 2 |
| Otto, T | 2 |
| Lümmen, G | 1 |
| Rübben, H | 2 |
| Kato, H | 1 |
| Koshida, K | 2 |
| Yokoyama, K | 1 |
| Mizokami, A | 2 |
| Namiki, M | 2 |
| Finkelstein, MP | 1 |
| Aynehchi, S | 1 |
| Samadi, AA | 1 |
| Drinis, S | 1 |
| Choudhury, MS | 1 |
| Tazaki, H | 1 |
| Konno, S | 1 |
| Miyagi, T | 1 |
| Hori, O | 1 |
| Konaka, H | 1 |
| Katoh, H | 1 |
| Kitagawa, Y | 1 |
| Egawa, M | 1 |
| Ogawa, S | 1 |
| Yu, D | 1 |
| Agrawal, S | 1 |
| Zhang, R | 1 |
| El-Rayes, BF | 1 |
| Black, CA | 1 |
| Ensley, JF | 1 |
| Zimmermann, A | 1 |
| Walt, H | 1 |
| Haller, U | 1 |
| Baas, P | 1 |
| Klein, SD | 1 |
| Droz, JP | 3 |
| Muracciole, X | 1 |
| Mottet, N | 1 |
| Ould Kaci, M | 1 |
| Vannetzel, JM | 1 |
| Albin, N | 1 |
| Culine, S | 1 |
| Rodier, JM | 1 |
| Misset, JL | 1 |
| Mackenzie, S | 1 |
| Cvitkovic, E | 1 |
| Benoit, G | 1 |
| Lu, S | 1 |
| Chen, GL | 1 |
| Ren, C | 1 |
| Kwabi-Addo, B | 1 |
| Epner, DE | 1 |
| Jenkins, DE | 1 |
| Oei, Y | 1 |
| Hornig, YS | 1 |
| Yu, SF | 1 |
| Dusich, J | 1 |
| Purchio, T | 1 |
| Contag, PR | 1 |
| Morant, R | 1 |
| Bernhard, J | 1 |
| Dietrich, D | 1 |
| Gillessen, S | 1 |
| Bonomo, M | 1 |
| Borner, M | 1 |
| Bauer, J | 1 |
| Cerny, T | 1 |
| Rochlitz, C | 1 |
| Wernli, M | 1 |
| Gschwend, A | 1 |
| Hanselmann, S | 1 |
| Hering, F | 1 |
| Schmid, HP | 1 |
| Le Pivert, P | 1 |
| Baust, JG | 3 |
| Gage, AA | 1 |
| Clarke, D | 1 |
| Baust, JM | 3 |
| Van Buskirk, R | 1 |
| Clarke, DM | 2 |
| Van Buskirk, RG | 2 |
| Birtle, AJ | 1 |
| Newby, JC | 1 |
| Harland, SJ | 3 |
| Mazeron, JJ | 1 |
| Nilsson, S | 1 |
| Strang, P | 1 |
| Ginman, C | 1 |
| Zimmermann, R | 1 |
| Edgren, M | 1 |
| Nordström, B | 1 |
| Ryberg, M | 1 |
| Kälkner, KM | 1 |
| Westlin, JE | 1 |
| Spicer, J | 1 |
| Plunkett, T | 1 |
| Somaiah, N | 1 |
| Chan, S | 1 |
| Kendall, A | 1 |
| Bolunwu, N | 1 |
| Pandha, H | 1 |
| Nomura, T | 1 |
| Yamasaki, M | 1 |
| Nomura, Y | 1 |
| Mimata, H | 1 |
| Boucher, PD | 1 |
| Im, MM | 1 |
| Freytag, SO | 1 |
| Shewach, DS | 1 |
| Rodney, A | 1 |
| Dieringer, P | 1 |
| Mathew, P | 1 |
| Jonasch, E | 1 |
| Tannir, N | 1 |
| Pagliaro, LC | 1 |
| Swanson, GP | 1 |
| Faulkner, J | 1 |
| Smalley, SR | 2 |
| Noble, MJ | 1 |
| Stephens, RL | 2 |
| O'Rourke, TJ | 1 |
| Weiss, GR | 1 |
| Quick, DP | 1 |
| Thompson, IM | 1 |
| Crawford, ED | 4 |
| Ferrero, JM | 1 |
| Chamorey, E | 1 |
| Oudard, S | 1 |
| Dides, S | 1 |
| Lesbats, G | 1 |
| Cavaglione, G | 1 |
| Nouyrigat, P | 1 |
| Foa, C | 1 |
| Kaphan, R | 1 |
| Vogt, T | 1 |
| Coras, B | 1 |
| Hafner, C | 1 |
| Landthaler, M | 1 |
| Kolodziej, M | 1 |
| Neubauer, MA | 1 |
| Rousey, SR | 1 |
| Pluenneke, RE | 1 |
| Perrine, G | 1 |
| Mull, S | 1 |
| Boehm, KA | 1 |
| Ilegbodu, D | 1 |
| Asmar, L | 1 |
| Li, Y | 1 |
| Shiraishi, T | 1 |
| Mikami, K | 1 |
| Takaha, N | 1 |
| Sakai, T | 1 |
| Mistry, SJ | 1 |
| Atweh, GF | 1 |
| Burkitt, M | 1 |
| Magee, C | 1 |
| O'Connor, D | 1 |
| Campbell, F | 1 |
| Cornford, P | 1 |
| Greenhalf, W | 1 |
| Rajeshkumar, NV | 1 |
| Matwyshyn, G | 1 |
| Gulati, A | 1 |
| Munoz, F | 1 |
| Franco, P | 1 |
| Ciammella, P | 1 |
| Clerico, M | 1 |
| Giudici, M | 1 |
| Filippi, AR | 1 |
| Ricardi, U | 1 |
| Mizukami, H | 1 |
| Yoshizawa, Y | 1 |
| Sasaya, S | 1 |
| Nemoto, H | 1 |
| Maezawa, K | 1 |
| Sanada, Y | 1 |
| Hung, H | 1 |
| Sanghera, P | 1 |
| Ho, K | 1 |
| Muscroft, T | 1 |
| Hartley, A | 1 |
| Friedman, J | 1 |
| Dunn, RL | 1 |
| Wood, D | 1 |
| Vaishampayan, U | 1 |
| Wu, A | 1 |
| Bradley, D | 1 |
| Montie, J | 1 |
| Sarkar, FH | 1 |
| Shah, RB | 1 |
| Hussain, M | 1 |
| Yang, JL | 1 |
| Qu, XJ | 1 |
| Yu, Y | 1 |
| Kohn, EC | 1 |
| Friedlander, ML | 1 |
| Takeuchi, H | 2 |
| Harada, T | 1 |
| Ohmura, H | 1 |
| Nishizawa, O | 1 |
| Tsuchida, S | 1 |
| Heim, ME | 1 |
| Eberwein, S | 1 |
| Georgi, M | 1 |
| Oberfield, RA | 1 |
| deKernion, JB | 2 |
| Lindner, A | 1 |
| DeWys, WD | 2 |
| Begg, CB | 1 |
| Brodovsky, H | 1 |
| Creech, R | 1 |
| Khandekar, J | 1 |
| Nagel, R | 1 |
| Leistenschneider, W | 1 |
| Könyves, I | 1 |
| Müntzing, J | 1 |
| Rozencweig, M | 1 |
| Murphy, GP | 16 |
| Slack, NH | 3 |
| Mittelman, A | 3 |
| Citrin, DL | 1 |
| Elson, P | 1 |
| Faul, P | 1 |
| Altwein, JE | 1 |
| Schmidt, JD | 9 |
| Burk, K | 3 |
| Gropp, C | 2 |
| Rodeck, G | 1 |
| Logothetis, CJ | 3 |
| Samuels, ML | 2 |
| von Eschenbach, AC | 2 |
| Trindade, A | 2 |
| Ogden, S | 1 |
| Grant, C | 1 |
| Johnson, DE | 9 |
| Yoshida, K | 2 |
| Negishi, T | 2 |
| Kobayashi, N | 1 |
| Saito, T | 1 |
| Owada, F | 1 |
| Ajima, J | 1 |
| Satake, I | 1 |
| Tari, K | 1 |
| Scott, WW | 8 |
| Gibbons, R | 1 |
| Prout, GR | 7 |
| Loening, S | 2 |
| Soloway, M | 1 |
| Pontes, JE | 2 |
| Eisenkraft, S | 1 |
| Huben, RP | 2 |
| Babaian, RJ | 1 |
| Hsu, SD | 1 |
| Kasimis, BS | 2 |
| Moran, EM | 2 |
| Miller, JB | 2 |
| Forbes, KA | 2 |
| Kaneshiro, CA | 2 |
| Poblet, MT | 1 |
| Williams, JL | 1 |
| Servadio, C | 5 |
| Mukamel, E | 4 |
| Lurie, H | 1 |
| Nissenkorn, I | 2 |
| Beckley, S | 2 |
| Wajsman, Z | 3 |
| Slack, N | 1 |
| Torti, FM | 1 |
| Carter, SK | 2 |
| Herr, HW | 1 |
| Muss, HB | 3 |
| Howard, V | 1 |
| Richards, F | 2 |
| White, DR | 1 |
| Jackson, DV | 1 |
| Cooper, MR | 1 |
| Stuart, JJ | 1 |
| Resnick, MI | 1 |
| Brodkin, R | 1 |
| Spurr, CL | 1 |
| Drago, JR | 9 |
| Worgul, TJ | 2 |
| Gallagher, C | 1 |
| Maeso, E | 1 |
| Pontes, E | 1 |
| Murphy, G | 2 |
| Smalley, RV | 1 |
| Bartolucci, AA | 1 |
| Hemstreet, G | 1 |
| Hester, M | 1 |
| Goldman, LB | 5 |
| Gershwin, ME | 7 |
| Hrushesky, WJ | 3 |
| Goldman, L | 1 |
| Jones, MA | 1 |
| Williams, G | 1 |
| Shinohara, N | 2 |
| Harabayashi, T | 1 |
| Matsuda, H | 1 |
| Nounaka, O | 1 |
| Nonomura, K | 1 |
| Koyanagi, T | 2 |
| Nagomori, S | 1 |
| Ohmuro, H | 2 |
| Matsumara, K | 1 |
| Demura, T | 2 |
| Neubauer, BL | 1 |
| Best, KL | 1 |
| Counts, DF | 1 |
| Goode, RL | 1 |
| Hoover, DM | 1 |
| Jones, CD | 1 |
| Sarosdy, MF | 1 |
| Shaar, CJ | 1 |
| Tanzer, LR | 1 |
| Merriman, RL | 1 |
| Breul, J | 2 |
| Jakse, G | 2 |
| Hartung, R | 2 |
| Dreicer, R | 2 |
| Forest, PK | 2 |
| Williams, RD | 1 |
| Kuriyama, M | 4 |
| Takeuchi, T | 4 |
| Takahashi, Y | 4 |
| Takeda, A | 1 |
| Ishihara, S | 1 |
| Ozeki, S | 1 |
| Ueno, K | 1 |
| Taniguchi, M | 1 |
| Yamamoto, N | 4 |
| Nagatani, Y | 1 |
| Daliani, DD | 1 |
| Eisenberg, PD | 1 |
| Weems, J | 1 |
| Lord, R | 1 |
| Fueger, R | 1 |
| Yagoda, A | 2 |
| Petrylak, D | 1 |
| Yamaoka, M | 1 |
| Yamamoto, T | 1 |
| Ikeyama, S | 1 |
| Sudo, K | 1 |
| Fujita, T | 1 |
| Lopez Lopez, R | 1 |
| van Rijswijk, RE | 1 |
| Wagstaff, J | 1 |
| Pinedo, HM | 1 |
| Peters, GJ | 1 |
| Huan, SD | 1 |
| Aitken, SE | 1 |
| Stewart, DJ | 1 |
| Sakai, H | 1 |
| Minami, Y | 1 |
| Kanetake, H | 1 |
| Saito, Y | 1 |
| Lokich, J | 1 |
| Fuhrman, GM | 1 |
| Ota, DM | 1 |
| Blumenstein, B | 1 |
| Saiers, JH | 2 |
| Rivkin, SE | 2 |
| Coltman, CA | 1 |
| Kuzel, TM | 1 |
| Tallman, MS | 1 |
| Shevrin, D | 1 |
| Braud, E | 1 |
| Kilton, L | 1 |
| Johnson, P | 1 |
| Kozlowski, J | 1 |
| Vogelzang, NJ | 1 |
| Blough, R | 1 |
| Benson, AB | 1 |
| Wozniak, AJ | 1 |
| Blumenstein, BA | 1 |
| Boileau, M | 1 |
| Fletcher, WS | 1 |
| Atkins, JN | 2 |
| Case, LD | 1 |
| Grote, T | 1 |
| McFarland, J | 1 |
| Glazier, DB | 1 |
| Heaney, JA | 1 |
| Amdur, RJ | 1 |
| Schned, AR | 1 |
| Harris, R | 1 |
| Fukui, I | 4 |
| Ernstoff, MS | 1 |
| See, WA | 1 |
| Wheeler, JA | 1 |
| Chao, D | 2 |
| von Schlippe, M | 1 |
| Forster, G | 1 |
| Lampel, A | 1 |
| Rohani, A | 1 |
| Otsuka, A | 1 |
| Ono, S | 1 |
| Hata, M | 1 |
| Ota, N | 1 |
| Roigas, J | 1 |
| Wallen, ES | 1 |
| Loening, SA | 1 |
| Moseley, PL | 1 |
| Yee, LK | 1 |
| Chu, E | 1 |
| Pan, BC | 1 |
| Chu, SH | 1 |
| Chen, TM | 1 |
| Lipsky, MH | 1 |
| Chu, MY | 1 |
| Calabresi, P | 1 |
| Berlin, JD | 1 |
| Propert, KJ | 1 |
| Trump, D | 1 |
| Wilding, G | 1 |
| Hudes, G | 1 |
| Glick, J | 1 |
| Burch, P | 1 |
| Keller, A | 1 |
| Loehrer, P | 1 |
| Toyoda, K | 1 |
| Kashiwagi, A | 1 |
| Nagamori, S | 1 |
| Ohzono, S | 1 |
| Deguchi, T | 2 |
| Yoh, M | 2 |
| Yasuda, M | 2 |
| Nakano, M | 2 |
| Kawada, Y | 3 |
| Shinoda, I | 3 |
| Michael, M | 1 |
| Moore, MJ | 1 |
| Kitsukawa, S | 1 |
| Kinn, T | 1 |
| Yoshida, T | 1 |
| Yonese, J | 1 |
| Izutami, T | 1 |
| Ishikawa, Y | 1 |
| Kim, CJ | 1 |
| Kushima, R | 1 |
| Okada, Y | 1 |
| Seto, A | 1 |
| Yang, CC | 1 |
| Hsu, CP | 1 |
| Yang, SD | 1 |
| Marshall, ME | 1 |
| Wolf, M | 1 |
| O'Rourke, M | 2 |
| Barnett, TC | 1 |
| Song, S | 1 |
| Wientjes, MG | 1 |
| Gan, Y | 1 |
| Au, JL | 1 |
| Pan, CC | 1 |
| Chiang, H | 1 |
| Chang, YH | 1 |
| Epstein, JI | 1 |
| Akaza, H | 2 |
| Aiba, K | 1 |
| Isonishi, S | 1 |
| Ogawa, O | 1 |
| Shibuya, M | 1 |
| Sone, S | 1 |
| Tsuruo, T | 1 |
| Noguchi, S | 1 |
| Hinotsu, S | 1 |
| Kono, S | 1 |
| Mikami, O | 1 |
| Blackledge, G | 1 |
| Vose, B | 1 |
| Stribling, D | 1 |
| Wullich, B | 1 |
| Endris, V | 1 |
| Rembrink, K | 1 |
| Stöckle, M | 1 |
| Siu, W | 1 |
| Wren, SM | 1 |
| King, C | 1 |
| Terris, MK | 1 |
| Recchia, F | 1 |
| Sica, G | 1 |
| De Filippis, S | 1 |
| Rosselli, M | 1 |
| Pompili, PL | 1 |
| Rea, S | 1 |
| Reimer, CL | 1 |
| Agata, N | 1 |
| Tammam, JG | 1 |
| Bamberg, M | 1 |
| Dickerson, WM | 1 |
| Kamphaus, GD | 1 |
| Rook, SL | 1 |
| Milhollen, M | 1 |
| Fram, R | 1 |
| Kalluri, R | 1 |
| Kufe, D | 1 |
| Kharbanda, S | 1 |
| Fox, RM | 2 |
| Woods, RL | 2 |
| Tattersall, MH | 1 |
| Brodie, GM | 1 |
| Maurer, RE | 4 |
| Wasserman, TH | 1 |
| Saroff, J | 4 |
| Joiner, JR | 2 |
| Gibbons, RP | 6 |
| Merrin, CE | 2 |
| Alyea, EP | 1 |
| Dees, JE | 1 |
| Glenn, JF | 1 |
| Chlebowski, RT | 1 |
| Hestorff, R | 1 |
| Sardoff, L | 1 |
| Weiner, J | 1 |
| Bateman, JR | 1 |
| Eckels, DD | 2 |
| Lachand, AT | 1 |
| Garcia-Giralt, E | 2 |
| Auvert, J | 1 |
| Juraschek, F | 1 |
| Mennecier, P | 1 |
| Pallangie, T | 1 |
| Moustafa, T | 1 |
| Eckels, D | 1 |
| Palmer, JM | 1 |
| Soloway, MS | 3 |
| Shippel, RM | 1 |
| Ikard, M | 1 |
| Buell, GV | 1 |
| Saiki, JH | 1 |
| Bergreen, PW | 1 |
| Block, NL | 1 |
| Camuzzi, F | 1 |
| Stover, B | 1 |
| Claflin, A | 1 |
| Troner, M | 1 |
| Politano, VA | 1 |
| Nevin, JE | 4 |
| Hoffman, AA | 1 |
| Staquet, M | 1 |
| Younus, S | 1 |
| Soterakis, J | 1 |
| Sossi, AJ | 1 |
| Chawla, SK | 1 |
| LoPresti, PA | 1 |
| Ogaard, S | 1 |
| Jensen, TS | 1 |
| Kane, RD | 2 |
| Stocks, LH | 1 |
| Paulson, DF | 4 |
| Tejada, F | 1 |
| Eisenberger, MA | 1 |
| Broder, LA | 1 |
| Cohen, MH | 1 |
| Simon, R | 1 |
| Reuter, HJ | 1 |
| Collier, D | 1 |
| Mickey, DD | 3 |
| Eagan, RT | 1 |
| Hahn, RG | 2 |
| Myers, RP | 1 |
| Schmidt, JE | 1 |
| Merrin, C | 1 |
| Etra, W | 1 |
| Baumgartner, G | 1 |
| Fosså, SD | 1 |
| Miller, A | 1 |
| Melnick, I | 3 |
| Baggerly, JT | 3 |
| Landes, R | 2 |
| Easley, CA | 2 |
| Singh, D | 1 |
| Doroshow, JH | 1 |
| Leong, L | 1 |
| Margolin, K | 1 |
| Akman, S | 1 |
| Raschko, J | 1 |
| Somlo, G | 1 |
| Morgan, R | 1 |
| Harrison, J | 1 |
| Cho, J | 1 |
| Nussbaum, B | 1 |
| Laurie, JA | 1 |
| Therneau, TM | 1 |
| Patel, SR | 1 |
| Mailliard, JA | 1 |
| Windschitl, HE | 1 |
| Twito, DI | 1 |
| Morton, RF | 1 |
| Krook, JE | 1 |
| Ohmori, H | 1 |
| Matsumura, Y | 1 |
| Ochi, J | 2 |
| Kobashi, K | 1 |
| Akebi, N | 1 |
| Saika, T | 1 |
| Nanba, K | 2 |
| Tanahashi, T | 2 |
| Josen, T | 1 |
| Nasu, Y | 1 |
| Ban, Y | 1 |
| Ito, Y | 1 |
| Maeda, S | 1 |
| Tada, K | 1 |
| Case, D | 1 |
| Brockschmidt, J | 1 |
| Schnell, FM | 1 |
| Grote, TH | 1 |
| West, JH | 1 |
| Anthony, S | 1 |
| Stanley, V | 1 |
| Kimler, BF | 1 |
| Evans, RG | 1 |
| Hansen, R | 1 |
| Moynihan, T | 1 |
| Beatty, P | 1 |
| Quebbeman, E | 1 |
| Libnoch, J | 1 |
| Schulte, W | 1 |
| Anderson, T | 1 |
| Tunn, UW | 1 |
| Goldschmidt, AJ | 1 |
| Peter, K | 1 |
| Becker, M | 1 |
| Goya, N | 2 |
| Yanagisawa, H | 1 |
| Nakamura, R | 2 |
| Toma, H | 2 |
| Yoshimoto, J | 1 |
| Saegusa, M | 1 |
| Hara, M | 1 |
| Akagi, T | 1 |
| Obama, T | 1 |
| Tsushima, T | 1 |
| Ozaki, Y | 1 |
| Hickey, D | 1 |
| Cant, J | 1 |
| Isurugi, K | 1 |
| Oishi, Y | 1 |
| Kitajima, K | 1 |
| Sawamura, Y | 1 |
| Baba, S | 1 |
| Otani, M | 1 |
| Harada, M | 1 |
| Gunji, A | 1 |
| Okada, K | 1 |
| Kanamaru, H | 1 |
| Yoshiki, T | 1 |
| Hashimura, T | 1 |
| Nishimura, K | 1 |
| Hida, S | 1 |
| Nishio, Y | 1 |
| Oishi, K | 1 |
| Yoshida, O | 1 |
| Yamauchi, T | 1 |
| Carvalho, L | 2 |
| Foulkes, K | 2 |
| Apple, JS | 1 |
| Baber, C | 1 |
| Putman, CE | 1 |
| Lupera, H | 1 |
| Piot, G | 2 |
| Lapleige, P | 1 |
| Theodore, C | 1 |
| Takeuchi, S | 2 |
| Higashi, Y | 2 |
| Andoh, M | 1 |
| Kihara, K | 2 |
| Kitahara, S | 2 |
| Horiuchi, S | 1 |
| Oshima, H | 2 |
| Portnoĭ, AS | 1 |
| Hofmann, W | 1 |
| Langkopf, B | 1 |
| Manni, A | 2 |
| Bartholomew, M | 1 |
| Caplan, R | 1 |
| Boucher, A | 1 |
| Santen, R | 1 |
| Lipton, A | 2 |
| Harvey, H | 2 |
| Simmonds, M | 2 |
| White-Hershey, D | 1 |
| Gordon, R | 2 |
| Hosoda, K | 1 |
| Kawai, T | 1 |
| Becher, R | 1 |
| Kurschel, E | 1 |
| Wandl, U | 1 |
| Kloke, O | 1 |
| Scheulen, M | 1 |
| Weinhardt, O | 1 |
| Höffken, K | 1 |
| Niederle, N | 1 |
| Bergner, S | 1 |
| Kobayashi, H | 1 |
| Sahashi, M | 1 |
| Obata, K | 1 |
| Sropp, C | 1 |
| Schultze-Seemann, W | 1 |
| de Riese, W | 2 |
| Onitsuka, S | 1 |
| Nakazawa, H | 1 |
| Priore, RL | 1 |
| Scardino, PT | 1 |
| Priore, R | 1 |
| Graham, SD | 1 |
| Walker, A | 1 |
| Cox, EB | 1 |
| Laszlo, J | 1 |
| Berry, WR | 1 |
| Smith, JB | 2 |
| Ghayad, PY | 2 |
| Dhabuwala, CB | 2 |
| Drelichman, A | 2 |
| Pierce, JM | 2 |
| Laplaige, P | 1 |
| Moran-Ribon, A | 1 |
| Savion, M | 1 |
| Santen, RJ | 1 |
| Boucher, AE | 1 |
| Rohner, T | 1 |
| Drago, J | 1 |
| Wettlaufer, J | 1 |
| Palangie, T | 1 |
| Dorval, T | 1 |
| Jouve, M | 1 |
| Pouillart, P | 1 |
| Metter, GE | 1 |
| Page, JP | 1 |
| Levi, JA | 1 |
| Tattersall, MN | 1 |
| Coates, AS | 1 |
| Löbenau, S | 1 |
| Pavone-Macaluso, M | 2 |
| Basso, A | 1 |
| Estevez, J | 1 |
| Li, MC | 1 |
| Kanwal, G | 1 |
| Kim, RH | 1 |
| Armstrong, JG | 1 |
| Furnari, S | 1 |
| Veroux, G | 1 |
| Mattea, E | 1 |
| Mayr, AC | 1 |
| Nagel, GA | 1 |
| Obrecht, JP | 1 |
| Catalona, WJ | 2 |
| Hoffman, A | 1 |
| Landes, RR | 1 |
| Easley, C | 1 |
| Greene, LF | 1 |
| Mulcahy, JJ | 1 |
| Warren, MM | 1 |
| Dockerty, MB | 1 |
| Chauvin, HF | 1 |
| Boileau, G | 1 |
| Piro, AJ | 1 |
| Lahiri, SR | 1 |
| Hall, TC | 1 |
| Wilson, CB | 1 |
| Winternitz, WW | 1 |
| Rush, BF | 1 |
| Walton, KN | 1 |
| Maddy, JA | 1 |
| Belitsky, P | 1 |
| Elhilali, MM | 1 |
| Oliver, JA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Master Protocol for Metastatic Hormone-Resistant Prostatic Carcinoma - Phase II Trials - Protocol 5: Capecitabine[NCT00006023] | Phase 2 | 0 participants | Interventional | 2000-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
14 reviews available for fluorouracil and Prostatic Neoplasms
| Article | Year |
|---|---|
Optimisation of replication-selective oncolytic adenoviral mutants in combination with chemotherapeutics.
Topics: Adenoviridae; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Combined Modality Therapy; Deoxycy | 2009 |
FOLFOX regimen in pancreatic acinar cell carcinoma: case report and review of the literature.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Acinar Cell; Fluorouracil; Humans; | 2012 |
Chemotherapy of hormonally unresponsive prostatic carcinoma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carmustine; Cispla | 1984 |
Chemotherapy principles in the treatment of prostatic cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Castration; Cisplatin; Cyclopho | 1984 |
[Advanced prostatic cancer: therapeutic modalities].
Topics: Acid Phosphatase; Antineoplastic Agents; Bromocriptine; Castration; Combined Modality Therapy; Cypro | 1984 |
Cytotoxic agents effective in prostate cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Doxorubicin; Fluorourac | 1983 |
The chemotherapy of prostatic adenocarcinoma.
Topics: Acid Phosphatase; Adenocarcinoma; Antineoplastic Agents; Cisplatin; Clinical Trials as Topic; Cyclop | 1980 |
Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Bone Neoplasms; Cisplatin; Clinical Trials as Topic; | 1993 |
[Successful multidisciplinary treatment for bladder cancer with priapism. A case report].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Comb | 1998 |
An aggressive approach to prostatic cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Castration; Cortisone; Cyclophosphamide; Diethylstilbes | 1977 |
Chemotherapy of prostatic cancer.
Topics: Aged; Alkylating Agents; Antibiotics, Antineoplastic; Antimetabolites; Antineoplastic Agents; Bromoc | 1975 |
[Chemotherapy of prostatic cancer].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; | 1985 |
Genitourinary-tract problems of the aged male.
Topics: Adenocarcinoma; Age Factors; Aged; Cyclophosphamide; Cyproterone; Diethylstilbestrol; Fluorouracil; | 1974 |
Proceedings: Non-hormonal cytotoxic agents in the treatment of prostatic adenocarcinoma.
Topics: Acid Phosphatase; Adenocarcinoma; Aniline Compounds; Bone Neoplasms; Cyclophosphamide; Evaluation St | 1973 |
69 trials available for fluorouracil and Prostatic Neoplasms
| Article | Year |
|---|---|
(188)Re-HEDP combined with capecitabine in hormone-refractory prostate cancer patients with bone metastases: a phase I safety and toxicity study.
Topics: Aged; Aged, 80 and over; Bone Neoplasms; Capecitabine; Deoxycytidine; Drug Resistance, Neoplasm; Eti | 2009 |
Phase II trial of capecitabine and weekly docetaxel for metastatic castrate resistant prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Confidence In | 2009 |
Impact of an all-oral capecitabine and vinorelbine combination regimen on functional status of elderly patients with advanced solid tumours: A multicentre pilot study of the French geriatric oncology group (GERICO).
Topics: Administration, Oral; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combi | 2010 |
Modular therapy approach in metastatic castration-refractory prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Bone Neoplasms; Capecitabine; Deoxycytidine; Dexamet | 2010 |
Phase II trial of oxaliplatin and capecitabine after progression to first-line chemotherapy in androgen-independent prostate cancer patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine | 2011 |
Phase II study of repeated single 24-hour infusion of low-dose 5-fluorouracil for palliation in symptomatic hormone-refractory prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antimetabolites, Antineoplastic; Drug | 2002 |
Phase II study of oxaliplatin versus oxaliplatin combined with infusional 5-fluorouracil in hormone refractory metastatic prostate cancer patients.
Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Disease-Free Survival; Dose-Response Relationship, Dru | 2003 |
Capecitabine in hormone-resistant metastatic prostatic carcinoma - a phase II trial.
Topics: Aged; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma; Deoxycytidine; Drug Resistance, Neop | 2004 |
Palliation of bone pain in prostate cancer using chemotherapy and strontium-89. A randomized phase II study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Double-Blind Method; Epirubici | 2005 |
Phase II study of oral capecitabine in patients with hormone-refractory prostate cancer.
Topics: Administration, Oral; Aged; Aged, 80 and over; Androgens; Capecitabine; Deoxycytidine; Drug Resistan | 2005 |
Phase II study of capecitabine combined with gemcitabine in the treatment of androgen-independent prostate cancer previously treated with taxanes.
Topics: Administration, Oral; Aged; Androgens; Capecitabine; Deoxycytidine; Dose-Response Relationship, Drug | 2006 |
Phase II trial evaluating a docetaxel-capecitabine combination as treatment for hormone-refractory prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, | 2006 |
Phase II trial of docetaxel/capecitabine in hormone-refractory prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabin | 2006 |
[Effectiveness of 5-fluorouracil combined with hormones in low dose as a basal treatment for prostatic carcinoma].
Topics: Aged; Allylestrenol; Combined Modality Therapy; Drug Therapy, Combination; Estrenes; Fluorouracil; H | 1984 |
Chemotherapy of hormonally unresponsive prostatic carcinoma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carmustine; Cispla | 1984 |
A comparative clinical trial of adriamycin and 5-fluorouracil in advanced prostatic cancer: prognostic factors and response.
Topics: Acid Phosphatase; Adenocarcinoma; Clinical Trials as Topic; Doxorubicin; Fluorouracil; Humans; Male; | 1983 |
[Cytostatic therapy of prostatic carcinoma. Current status and personal results].
Topics: Aged; Antineoplastic Agents; Clinical Trials as Topic; Cyclophosphamide; Drug Resistance; Drug Thera | 1983 |
Experiences with estramustine phosphate (Estracyt, Emcyt) in prostate cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Castration; Cisplatin; Clinical Tria | 1983 |
Treatment of metastatic prostate cancer. An analysis of response criteria in patients with measurable soft tissue disease.
Topics: Acid Phosphatase; Aged; Bone Neoplasms; Clinical Trials as Topic; Doxorubicin; Drug Evaluation; Fluo | 1984 |
The chemotherapy of prostatic carcinoma.
Topics: Antineoplastic Agents; Cyclophosphamide; Fluorouracil; Humans; Immunity, Innate; Male; Neoplasm Stag | 1980 |
The chemotherapy of prostatic adenocarcinoma.
Topics: Acid Phosphatase; Adenocarcinoma; Antineoplastic Agents; Cisplatin; Clinical Trials as Topic; Cyclop | 1980 |
Cyclophosphamide, methotrexate and 5-fluorouracil combination chemotherapy versus chloroethyl-cyclohexy-nitrosourea in the treatment of metastatic prostatic cancer.
Topics: Aged; Antineoplastic Agents; Carcinoma; Cyclophosphamide; Drug Therapy, Combination; Fluorouracil; F | 1982 |
Cyclophosphamide versus cyclophosphamide, methotrexate, and 5-fluorouracil in advanced prostatic cancer: a randomized trial.
Topics: Aged; Bone Neoplasms; Cyclophosphamide; Drug Evaluation; Drug Therapy, Combination; Fluorouracil; Hu | 1981 |
A phase II evaluation of a 3-drug combination of cyclophosphamide, doxorubicin and 5-fluorouracil and of 5-fluorouracil in patients with advanced bladder carcinoma or stage D prostatic carcinoma.
Topics: Adenocarcinoma; Carcinoma, Transitional Cell; Cyclophosphamide; Doxorubicin; Drug Evaluation; Drug T | 1981 |
[5-Fluorouracil and alpha-2a interferon in patients with hormone-refractory prostate cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Drug Resistance, | 1995 |
Phase II trial of 5-fluorouracil and alpha-2b interferon in patients with hormone-refractory metastatic prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Drug Admini | 1994 |
Intra-arterial chemotherapy using a reservoir for endocrine-refractory prostate cancer.
Topics: Abdominal Muscles; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplati | 1994 |
The results of a phase II randomized trial comparing 5-fluorouracil and 5-fluorouracil plus alpha-interferon: observations on the design of clinical trials for androgen-independent prostate cancer.
Topics: Adenocarcinoma; Aged; Disease Progression; Fluorouracil; Humans; Interferon-alpha; Male; Prospective | 1995 |
5-fluorouracil and high dose folinic acid in hormone-refractory metastatic prostate cancer: a phase II study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Diarrhea; Fluorouracil; Humans; Leucovorin; Ma | 1994 |
Chemo-endocrine therapy for prostate cancer with bone metastasis. Nagasaki Prostate Cancer Research Group.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Bone | 1994 |
A Phase II study of continuous infusion 5-fluorouracil in advanced hormone refractory prostate cancer: an Illinois cancer center study.
Topics: Fluorouracil; Humans; Illinois; Infusions, Parenteral; Male; Prostatic Neoplasms | 1994 |
Doxorubicin, mitomycin C and 5-fluorouracil in the treatment of hormone refractory adenocarcinoma of the prostate: a Southwest Oncology Group study.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Fluorouracil; Humans; M | 1993 |
A phase II study of continuous infusion 5-fluorouracil in advanced hormone refractory prostate cancer. An Illinois Cancer Center Study.
Topics: Aged; Fluorouracil; Hormones; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Metastasis | 1993 |
Cyclophosphamide, methotrexate, and 5-fluorouracil in the treatment of metastatic prostate cancer. A Southwest Oncology Group study.
Topics: Acid Phosphatase; Adenocarcinoma; Aged; Alkaline Phosphatase; Antineoplastic Combined Chemotherapy P | 1993 |
Leucovorin and high-dose fluorouracil in metastatic prostate cancer. A phase II trial of the piedmont Oncology Association.
Topics: Aged; Aged, 80 and over; Antidotes; Antimetabolites, Antineoplastic; Fluorouracil; Humans; Leucovori | 1996 |
5-fluorouracil and allopurinol combined with recombinant interferon-alpha 2b in the treatment of patients with advanced prostate cancer: a phase I/II study.
Topics: Aged; Allopurinol; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined C | 1996 |
Brachytherapy and continuous infusion 5-fluorouracil for treatment of locally advanced, lymph node negative, prostate cancer: a phase I trial.
Topics: Aged; Antineoplastic Agents; Brachytherapy; Combined Modality Therapy; Fluorouracil; Gold Radioisoto | 1996 |
A phase II study of continuous infusion 5-fluorouracil (5-FU) with epirubicin and cisplatin in metastatic, hormone-resistant prostate cancer: an active new regimen.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocol | 1997 |
5-Fluorouracil versus folinic acid and 5-fluorouracil in advanced, hormone-resistant prostate cancer: a prospective randomized pilot trial.
Topics: Aged; Androgens; Antimetabolites, Antineoplastic; Drug Resistance, Neoplasm; Drug Therapy, Combinati | 1997 |
5-Fluorouracil and leucovorin therapy in patients with hormone refractory prostate cancer: an Eastern Cooperative Oncology Group phase II study (E1889).
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antidotes; Antimetabolites, Antineoplastic; Fluorouracil; H | 1998 |
5-fluorouracil and low-dose recombinant interferon-alpha-2a in patients with hormone-refractory adenocarcinoma of the prostate.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Combined Chemotherapy | 1998 |
[Intra-arterial chemotherapy via reservoir system for advanced bladder cancer and prostate cancer].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Catheters, Indwellin | 1999 |
Phase II study of epirubicin, mitomycin C, and 5-fluorouracil in hormone-refractory prostatic carcinoma.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoembr | 2001 |
[Chemotherapy of advanced prostate cancer].
Topics: Chlorambucil; Clinical Trials as Topic; Cyclophosphamide; Dacarbazine; Diethylstilbestrol; Drug Eval | 1977 |
Cyclophosphamide (NSC 26271) versus the combination of adriamycin (NSC 123127), 5-fluorouracil (NSC 19893), and cyclophosphamide in the treatment of metastatic prostatic cancer: a randomized trial.
Topics: Adenocarcinoma; Aged; Bone Marrow; Clinical Trials as Topic; Cyclophosphamide; Digestive System; Dox | 1978 |
The randomized clinical trial: a prerequisite for rational therapy.
Topics: Clinical Trials as Topic; Cyclophosphamide; Diethylstilbestrol; Double-Blind Method; Doxorubicin; Fe | 1976 |
5-fluorouracil versus CCNU in the treatment of metastatic prostatic cancer.
Topics: Drug Evaluation; Fluorouracil; Humans; Leukopenia; Lomustine; Male; Neoplasm Metastasis; Nitrosourea | 1977 |
Chemotherapy of advanced prostatic cancer. Evaluation of response parameters.
Topics: Aged; Body Weight; Bone Marrow Examination; Bone Neoplasms; Cyclophosphamide; Drug Evaluation; Fluor | 1976 |
The continued evaluation of the effects of chemotherapy in patients with advanced carcinoma of the prostate.
Topics: Carcinoma; Cyclophosphamide; Evaluation Studies as Topic; Fluorouracil; Humans; Male; Neoplasm Recur | 1976 |
Prostatic carcinoma. relationship between primary tumor, histologic grade, and response to chemotherapy.
Topics: Carcinoma; Cyclophosphamide; Fluorouracil; Humans; Male; Prostatic Neoplasms | 1976 |
Adriamycin (NSC-123127) versus 5-fluorouracil (NSC-19893) and cyclophosphamide (NSC-26271) in the treatment of metastatic prostate cancer.
Topics: Aged; Cyclophosphamide; Doxorubicin; Drug Therapy, Combination; Fluorouracil; Humans; Male; Middle A | 1976 |
The continued evaluation of the effects of chemotherapy in patients with advanced carcinoma of the prostate.
Topics: Carcinoma; Cyclophosphamide; Fluorouracil; Humans; Male; Maryland; Prognosis; Prostatic Neoplasms | 1976 |
Chemotherapy of advanced prostatic carcinoma with cyclophosphamide or 5-fluorouracil: results of first national randomized study.
Topics: Clinical Trials as Topic; Cyclophosphamide; Drug Evaluation; Fluorouracil; Humans; Male; Prostatic N | 1975 |
Chemotherapy of advanced carcinoma of the prostate with 5-fluorouracil, cyclophosphamide and adriamycin.
Topics: Adenocarcinoma; Aged; Alopecia; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Drug Evalua | 1976 |
Phase II trial of 5-fluorouracil, high-dose leucovorin calcium, and dipyridamole in advanced prostate cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dipyridamole; Fluorouracil; Humans; Leucovorin | 1992 |
Chemotherapy for hormonally refractory advanced prostate carcinoma. A comparison of combined versus sequential treatment with mitomycin C, doxorubicin, and 5-fluorouracil.
Topics: Acid Phosphatase; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Doxorubicin; Fluo | 1992 |
High-dose 24-hour infusion of 5-fluorouracil in metastatic prostate cancer. A phase II trial of the Piedmont Oncology Association.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Drug Evaluation; Fluorouracil; Humans; Infusions, In | 1991 |
Continuous systemic 5-fluorouracil infusion in refractory prostatic cancer.
Topics: Drug Evaluation; Fluorouracil; Humans; Infusions, Intravenous; Male; Prostatic Neoplasms | 1991 |
Failure of chemotherapy to prolong life in patients with metastatic prostate cancer who have failed androgen deprivation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Cyclophosphamid | 1988 |
A prospective, randomized controlled study on the treatment of stage C and stage D prostatic cancer with estracyt in combination with other chemotherapeutic agents.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Diethylstilbestr | 1988 |
Androgen priming and chemotherapy in advanced prostate cancer: evaluation of determinants of clinical outcome.
Topics: Acid Phosphatase; Aged; Aminoglutethimide; Antineoplastic Combined Chemotherapy Protocols; Clinical | 1988 |
[A randomized trial of chemotherapy of advanced prostatic cancer with ifosfamide alone versus ifosfamide, 5-fluorouracil and cisplatin (preliminary report)].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Evaluation; | 1988 |
5-Fluorouracil and 5-formyltetrahydrofolate in advanced malignancies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Colorect | 1988 |
Hormone-refractory metastatic prostatic cancer treated with methotrexate, cyclophosphamide plus adriamycin, cis-platinum plus 5-fluorouracil plus cyclophosphamide. National Prostatic Cancer Project randomized trial.
Topics: Acid Phosphatase; Alkaline Phosphatase; Antineoplastic Agents; Antineoplastic Combined Chemotherapy | 1988 |
Results of another trial of chemotherapy with and without hormones in patients with newly diagnosed metastatic prostate cancer.
Topics: Blood Platelets; Carcinoma; Clinical Trials as Topic; Cyclophosphamide; Diethylstilbestrol; Estramus | 1986 |
Value of cyclophosphamide or melphalan as combined chemotherapy in hormonally unresponsive prostatic carcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cyclophosp | 1986 |
Androgen depletion and repletion as a means of potentiating the effect of cytotoxic chemotherapy in advanced prostate cancer.
Topics: Aminoglutethimide; Antineoplastic Combined Chemotherapy Protocols; Cell Division; Combined Modality | 1987 |
Cyclophosphamide versus 5-fluorouracil, doxorubicin, and mitomycin C (FAM') in the treatment of hormone-resistant metastatic carcinoma of the prostate: a preliminary report of a randomized trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; | 1985 |
Randomized trial of combination chemotherapy in hormone-resistant metastatic prostate carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cyclophosphamide; Do | 1985 |
199 other studies available for fluorouracil and Prostatic Neoplasms
| Article | Year |
|---|---|
Synthesis and biological evaluation of novel cytotoxic phospholipids for prostate cancer.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; CHO Cells; Cricetinae; Humans; Male; Phospholipids | 2004 |
Synthesis and antiproliferative activity of 2-aryl-4-oxo-thiazolidin-3-yl-amides for prostate cancer.
Topics: Amides; Antineoplastic Agents; Cell Line, Tumor; Drug Screening Assays, Antitumor; Humans; Male; Pro | 2004 |
Discovery of 2-arylthiazolidine-4-carboxylic acid amides as a new class of cytotoxic agents for prostate cancer.
Topics: Amides; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Drug Screening Assays, Antitumor; Humans | 2005 |
SAR studies of 2-arylthiazolidine-4-carboxylic acid amides: a novel class of cytotoxic agents for prostate cancer.
Topics: Amides; Antineoplastic Agents; Carboxylic Acids; Cell Line; Cell Proliferation; Humans; Inhibitory C | 2005 |
Novel 2,4,5-trisubstituted oxazole derivatives: synthesis and antiproliferative activity.
Topics: Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; Hu | 2009 |
Design and synthesis of spiro derivatives of parthenin as novel anti-cancer agents.
Topics: 4-Butyrolactone; Animals; Antineoplastic Agents; Blotting, Western; Carcinoma, Ehrlich Tumor; Cell C | 2011 |
New adamantane phenylalkylamines with σ-receptor binding affinity and anticancer activity, associated with putative antagonism of neuropathic pain.
Topics: Adamantane; Animals; Antineoplastic Agents; Apoptosis; Caspase 3; Cell Cycle; Cell Proliferation; Fe | 2012 |
Stereoselective synthesis and anti-proliferative effects on prostate cancer evaluation of 5-substituted-3,4-diphenylfuran-2-ones.
Topics: Antineoplastic Agents; Apoptosis; Cell Proliferation; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxyge | 2013 |
Design and evaluation of novel oxadiazole derivatives as potential prostate cancer agents.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cell | 2016 |
Antiproliferative and Anti-inflammatory Withanolides from Physalis angulata.
Topics: Anti-Inflammatory Agents; Antineoplastic Agents, Phytogenic; Crystallography, X-Ray; Drug Screening | 2016 |
Synthesis and biological evaluation of some novel triazole hybrids of curcumin mimics and their selective anticancer activity against breast and prostate cancer cell lines.
Topics: Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Breast Neoplasms; Cell Cycle Checkpoin | 2016 |
Novel indazole skeleton derivatives containing 1,2,3-triazole as potential anti-prostate cancer drugs.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, | 2022 |
Design, synthesis, and evaluation of novel (E)-N'-(3-allyl-2-hydroxy)benzylidene-2-(4-oxoquinazolin-3(4H)-yl)acetohydrazides as antitumor agents.
Topics: Antineoplastic Agents; Benzylidene Compounds; Cell Line, Tumor; Colonic Neoplasms; Fluorouracil; Hum | 2022 |
Synergistic Interaction of CPP2 Coupled with Thiazole Derivates Combined with Clotrimazole and Antineoplastic Drugs in Prostate and Colon Cancer Cell Lines.
Topics: Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell | 2021 |
Discovery of SI 1/20 and SI 1/22 as Mutual Prodrugs of 5-Fluorouracil and Imidazole-Based Heme Oxygenase 1 Inhibitor with Improved Cytotoxicity in DU145 Prostate Cancer Cells.
Topics: Cell Line; Fluorouracil; Heme Oxygenase-1; Humans; Imidazoles; Male; Prodrugs; Prostate; Prostatic N | 2023 |
[PRIMARY SQUAMOUS CELL CARCINOMA OF THE PROSTATE: A CASE REPORT].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Fluoroura | 2019 |
Toxicity profile of taxanes in Tunisian cancer patients: A retrospective study of 90 cases.
Topics: Adult; Aged; Alopecia; Antineoplastic Agents; Breast Neoplasms; Cisplatin; Digestive System Diseases | 2021 |
Clopidogrel in a combined therapy with anticancer drugs-effect on tumor growth, metastasis, and treatment toxicity: Studies in animal models.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Clopidogrel; Fluorouracil; Humans; Male; Mice; Neo | 2017 |
Persisting ring chromosomes detected by mFISH in lymphocytes of a cancer patient-a case report.
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Blood Cells; Chromosome Aberratio | 2013 |
Attenuation of nucleoside and anti-cancer nucleoside analog drug uptake in prostate cancer cells by Cimicifuga racemosa extract BNO-1055.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Bromodeoxyuridine; Cell Line; Ce | 2013 |
Impact of chemotherapy on normal tissue complication probability models of acute hematologic toxicity in patients receiving pelvic intensity modulated radiation therapy.
Topics: Aged; Antineoplastic Agents; Anus Neoplasms; Bone Marrow; Chemoradiotherapy; Cisplatin; Drug Adminis | 2013 |
shRNA-mediated GSTP1 gene silencing enhances androgen-independent cell line DU145 chemosensitivity.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Line, Tumor; Cel | 2014 |
Fat composition changes in bone marrow during chemotherapy and radiation therapy.
Topics: Adipose Tissue; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Co | 2014 |
Evaluation of the cytotoxic effects of PLGA coated iron oxide nanoparticles as a carrier of 5- fluorouracil and mega-voltage X-ray radiation in DU145 prostate cancer cell line.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; Chemoradiotherapy; Coated Materials, B | 2014 |
Polymeric nanomedicine for tumor-targeted combination therapy to elicit synergistic genotoxicity against prostate cancer.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Doxorubicin; Drug Carriers; Drug Delivery Systems; | 2015 |
Prostate Cancer Heterogeneous High-Metastatic Multi-Organ-Colonizing Chemo-Resistant Variants Selected by Serial Metastatic Passage in Nude Mice Are Highly Enriched for Multinucleate Giant Cells.
Topics: Animals; Antineoplastic Agents; Bone Neoplasms; Cell Line, Tumor; Cell Survival; Cisplatin; Doxorubi | 2015 |
Reply to I. Gounaris and M. Hall et al.
Topics: Fluorouracil; Humans; Leucovorin; Neoadjuvant Therapy; Prostatic Neoplasms; Rectal Neoplasms | 2017 |
[Bystander effect of target-regulated uracil phosphoribosyltransferase/5-fluorouracil suicide gene system on prostate cancer cell].
Topics: Antimetabolites, Antineoplastic; Bystander Effect; Cell Line, Tumor; Cell Survival; Fluorouracil; Ge | 2008 |
Specific targeting of prostate cancer cells in vitro by the suicide gene/prodrug system, uracil phosphoribosyltransferase/5-fluorouracil, under the control of prostate-specific membrane antigen promoter/enhancer.
Topics: Antigens, Surface; Antineoplastic Agents; Cell Line, Tumor; Enhancer Elements, Genetic; Escherichia | 2009 |
Overexpression of orotate phosphoribosyl transferase in hormone-refractory prostate cancer.
Topics: Antineoplastic Agents; Dihydrouracil Dehydrogenase (NADP); Drug Resistance, Neoplasm; Fluorouracil; | 2009 |
Effective combined chemotherapy for prostatic ductal adenocarcinoma: continuous venous infusion of 5-fluorouracil and low-dose consecutive cisplatin.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ductal; Cisplatin; Fluorouracil; Humans; | 2003 |
E2F1 Induces tumor cell survival via nuclear factor-kappaB-dependent induction of EGR1 transcription in prostate cancer cells.
Topics: Apoptosis; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; E2F1 Transcription Factor; Ea | 2009 |
Expression of the bifunctional suicide gene CDUPRT increases radiosensitization and bystander effect of 5-FC in prostate cancer cells.
Topics: Animals; Blotting, Western; Bystander Effect; Cell Line, Tumor; Coculture Techniques; Cytosine Deami | 2009 |
Percutaneous tumor ablation: microencapsulated echo-guided interstitial chemotherapy combined with cryosurgery increases necrosis in prostate cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Combined Modality Therapy; Cryosurgery; | 2009 |
Concurrent and sequential administration of chemotherapy and the Mammalian target of rapamycin inhibitor temsirolimus in human cancer cells and xenografts.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Cycle; Cell Line, Tu | 2009 |
Variations in the content of CD34+ cells in the peripheral blood of cancer patients receiving out-patient chemotherapy.
Topics: Adolescent; Adult; Aged; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Breast Neop | 1999 |
Targeted delivery of an anti-cancer agent via steroid coupled liposomes.
Topics: Animals; Antineoplastic Agents; Drug Carriers; Drug Compounding; Drug Delivery Systems; Fluorouracil | 2009 |
Adipose tissue-derived mesenchymal stem cells expressing prodrug-converting enzyme inhibit human prostate tumor growth.
Topics: Animals; Cell Line, Tumor; Cytosine Deaminase; Flucytosine; Fluorouracil; Humans; Male; Mesenchymal | 2010 |
Metastatic prostatic adenocarcinoma mimicking inflammatory breast carcinoma: a case report.
Topics: Adenocarcinoma; Aged; Anilides; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms, Ma | 2010 |
Prostate apoptosis response protein 4 sensitizes human colon cancer cells to chemotherapeutic 5-FU through mediation of an NF kappaB and microRNA network.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Blotting, Western; Chromatin Immuno | 2010 |
Preliminary experience with bladder preservation for lower rectal cancers involving the lower urinary tract.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Feasibility | 2010 |
Neural cell adhesion molecule 2 as a target molecule for prostate and breast cancer gene therapy.
Topics: Adenoviridae; Amino Acid Sequence; Animals; Animals, Newborn; Antibodies, Monoclonal; Antimetabolite | 2011 |
Hydroxyflutamide enhances cellular sensitivity to 5-fluorouracil by suppressing thymidylate synthase expression in bicalutamide-resistant human prostate cancer cells.
Topics: Androgen Antagonists; Anilides; Antimetabolites, Antineoplastic; Carcinoma; Cell Line, Tumor; Drug E | 2011 |
Low-dose docetaxel enhances the sensitivity of S-1 in a xenograft model of human castration resistant prostate cancer.
Topics: Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Docetaxel; Drug Com | 2012 |
Up-regulation of insulin-like growth factor-binding protein 3 by 5-fluorouracil (5-FU) leads to the potent anti-proliferative effect of androgen deprivation therapy combined with 5-FU in human prostate cancer cell lines.
Topics: Androgen Antagonists; Androgens; Anilides; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell | 2011 |
[Comments on "Normal tissue tolerance to external beam radiotherapy: Small bowel" by Martin et al. (Cancer Radiother 14:350-3)].
Topics: Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Genital Neoplasms, Female; H | 2011 |
[Successful combined treatment with maximal androgen blockade (MAB), intra arterial chemotherapy and radiation for advanced prostatic ductal adenocarcinoma : report of two cases].
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, | 2011 |
Quantitative analysis of the enzymes associated with 5-fluorouracil metabolism in prostate cancer biopsies.
Topics: Dihydrouracil Dehydrogenase (NADP); Fluorouracil; Gene Expression; Humans; Lasers; Male; Microdissec | 2011 |
Novel anticancer polymeric conjugates of activated nucleoside analogues.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Cholesterol; Female; Fluorouracil; Human | 2011 |
Radiotherapy: the importance of local control in pancreatic cancer.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; M | 2011 |
Evaluation of oral chemotherapy with capecitabine and cyclophosphamide plus thalidomide and prednisone in prostate cancer patients.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cyclophosp | 2012 |
Treatment of prostate carcinoma with (galectin-3)-targeted HPMA copolymer-(G3-C12)-5-Fluorouracil conjugates.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Drug Carriers; Drug Delivery Systems; En | 2012 |
Dual-mode interaction between quercetin and DNA-damaging drugs in cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Apoptosis; bcl-2-Associated X Protein; | 2012 |
A primary signet ring cell carcinoma of the prostate with bone metastasis with impressive response to FOLFOX and cetuximab.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherap | 2012 |
[Prostate carcinoma with squamous differentiation after combination endocrine therapy: a case report].
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Anilides; Antimetabolites, Antineoplastic; Antineoplasti | 2012 |
Effects of genetically engineered stem cells expressing cytosine deaminase and interferon-beta or carboxyl esterase on the growth of LNCaP rrostate cancer cells.
Topics: Animals; Camptothecin; Carboxylesterase; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell S | 2012 |
Cytosine deaminase and thymidine kinase gene therapy in a Dunning rat prostate tumour model: absence of bystander effects and characterisation of 5-fluorocytosine metabolism with 19F-NMR spectroscopy.
Topics: Animals; Antimetabolites; Bystander Effect; Cell Survival; Cytosine Deaminase; Disease Models, Anima | 2002 |
Synergistic cytotoxicity and apoptosis of JTE-522, a selective cyclooxygenase-2 inhibitor, and 5-fluorouracil against bladder cancer.
Topics: Antimetabolites, Antineoplastic; Apoptosis; bcl-2-Associated X Protein; bcl-X Protein; Benzenesulfon | 2002 |
Adenovirus mediated prostate specific enzyme prodrug gene therapy using prostate specific antigen promoter enhanced by the Cre-loxP system.
Topics: Adenoviridae; Animals; Antimetabolites, Antineoplastic; Cytosine Deaminase; Enhancer Elements, Genet | 2002 |
Potential benefits of combining cytosine deaminase/5-fluorocytosine gene therapy and irradiation for prostate cancer: experimental study.
Topics: Animals; Antimetabolites; Combined Modality Therapy; Cytosine Deaminase; Flucytosine; Fluorouracil; | 2002 |
Chemosensitization of carmustine with maitake beta-glucan on androgen-independent prostatic cancer cells: involvement of glyoxalase I.
Topics: Agaricales; Androgens; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Proto | 2002 |
Gene therapy for prostate cancer using the cytosine deaminase/uracil phosphoribosyltransferase suicide system.
Topics: Adenoviridae; Animals; Antimetabolites, Antineoplastic; Cell Line; Cytosine Deaminase; Fluorouracil; | 2003 |
Experimental therapy of human prostate cancer by inhibiting MDM2 expression with novel mixed-backbone antisense oligonucleotides: in vitro and in vivo activities and mechanisms.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin | 2003 |
Hormone-refractory prostate cancer responding to capecitabine.
Topics: Adenocarcinoma; Aged; Alkaline Phosphatase; Antimetabolites, Antineoplastic; Antineoplastic Agents, | 2003 |
Effects of chlorin-mediated photodynamic therapy combined with fluoropyrimidines in vitro and in a patient.
Topics: Apoptosis; Breast Neoplasms; Carcinoma, Basal Cell; Floxuridine; Fluorouracil; Humans; Male; Mesopor | 2003 |
Methionine restriction selectively targets thymidylate synthase in prostate cancer cells.
Topics: Antimetabolites, Antineoplastic; Cell Division; Fluorouracil; Folic Acid; Humans; Male; Methionine; | 2003 |
Cytosine deaminase versus thymidine kinase: a comparison of the antitumor activity.
Topics: Animals; Antiviral Agents; Cytosine Deaminase; Escherichia coli; Fluorouracil; Ganciclovir; Genetic | 2003 |
Bioluminescent imaging (BLI) to improve and refine traditional murine models of tumor growth and metastasis.
Topics: Animals; Cell Line, Tumor; Colonic Neoplasms; Fluorouracil; Humans; Image Interpretation, Computer-A | 2003 |
Ultrasound guided combined cryoablation and microencapsulated 5-Fluorouracil inhibits growth of human prostate tumors in xenogenic mouse model assessed by luminescence imaging.
Topics: Animals; Combined Modality Therapy; Cryosurgery; Diagnostic Imaging; Fluorouracil; Genetic Engineeri | 2004 |
Cryosurgery--a putative approach to molecular-based optimization.
Topics: Antineoplastic Agents; Apoptosis; Caspase Inhibitors; Caspases; Cell Death; Cell Line, Tumor; Cell S | 2004 |
Addition of anticancer agents enhances freezing-induced prostate cancer cell death: implications of mitochondrial involvement.
Topics: Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Cell Death; Cell Line, Tumor; Chemothe | 2004 |
Epirubicin carboplatin and 5-fluorouracil (ECarboF) chemotherapy in metastatic hormone refractory prostate cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carboplatin; E | 2004 |
[Minutes of the 23th meeting of the European Society for Therapeutic Radiology and Oncology (ESTRO). Amsterdam, 24-28 October 2004].
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Amifostine; Antineoplastic Agents, Hormonal; Antineo | 2005 |
Orthotopic metastatic (MetaMouse) models for discovery and development of novel chemotherapy.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Camptothecin; Cisplatin; Colonic Neoplasms; | 2005 |
Expression of the inhibitors of apoptosis proteins in cisplatin-resistant prostate cancer cells.
Topics: Apoptosis; Baculoviral IAP Repeat-Containing 3 Protein; Bisbenzimidazole; Cell Line, Tumor; Cell Pro | 2005 |
A novel mechanism of synergistic cytotoxicity with 5-fluorocytosine and ganciclovir in double suicide gene therapy.
Topics: Adenoviridae; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cytosine Deaminase; | 2006 |
Locally advanced prostate cancer treated with concomitant radiation and 5-fluorouracil: Southwest Oncology Group Study 9024.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Fluorouracil; Huma | 2006 |
Antiangiogenic therapy in metastatic prostate carcinoma complicated by cutaneous lupus erythematodes.
Topics: Angiogenesis Inhibitors; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Capecit | 2006 |
The significance of the expression of dihydropyrimidine dehydrogenase in prostate cancer.
Topics: Aged; Animals; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Dihydrouracil Dehydrogenase | 2007 |
Therapeutic interactions between stathmin inhibition and chemotherapeutic agents in prostate cancer.
Topics: Adenoviridae; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Combined Modality Th | 2006 |
Potentiation of chemotherapeutics by the Hsp90 antagonist geldanamycin requires a steady serum condition.
Topics: Antineoplastic Agents; Apoptotic Protease-Activating Factor 1; Benzoquinones; Cell Line, Tumor; Cell | 2007 |
IRL-1620, a tumor selective vasodilator, augments the uptake and efficacy of chemotherapeutic agents in prostate tumor rats.
Topics: Animals; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Biolog | 2007 |
Squamous cell carcinoma of the prostate: long-term survival after combined chemo-radiation.
Topics: Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Disease | 2007 |
[A case of advanced colon cancer invading the rectum effectively treated with chemoradiation therapy before surgery].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Drug Admi | 2007 |
Bevacizumab plus 5-fluorouracil induce growth suppression in the CWR-22 and CWR-22R prostate cancer xenografts.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis | 2007 |
Neoadjuvant chemotherapy enables R0 resection of locally advanced rectal cancer in a patient with a previously irradiated pelvis.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Trans | 2007 |
Neoadjuvant docetaxel and capecitabine in patients with high risk prostate cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Docetaxel; | 2008 |
Selective sensitivity to carboxyamidotriazole by human tumor cell lines with DNA mismatch repair deficiency.
Topics: Antineoplastic Agents; Apoptosis; Calcium Channel Blockers; Cell Cycle; Cell Line, Tumor; Chromosome | 2008 |
Efficacy and side effects of the regional arterial infusion of anti-cancer drugs combined with direct hemoperfusion in malignancies of the urinary tract.
Topics: Adenocarcinoma; Adult; Aged; Bleomycin; Carcinoma, Transitional Cell; Charcoal; Doxorubicin; Female; | 1982 |
Palliative therapy of pelvic tumors by intra-arterial infusion of cytotoxic drugs.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Colonic Neoplasms; Doxorubicin; Fe | 1983 |
Intra-arterial infusion in tumors of the pelvis.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Combined Modality T | 1983 |
The therapeutic effect of concurrent administration of 5-fluorouracil and allylestrenol or hexestrol in small doses on prostatic carcinoma.
Topics: Aged; Allylestrenol; Drug Therapy, Combination; Estrenes; Fluorouracil; Hexestrol; Humans; Male; Mid | 1981 |
[Treatment of metastasizing prostatic carcinoma with DMF. Presentation of a prospective study].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Fluorouracil; Humans; M | 1983 |
Doxorubicin, mitomycin-C, and 5-fluorouracil (DMF) in the treatment of metastatic hormonal refractory adenocarcinoma of the prostate, with a note on the staging of metastatic prostate cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Doxorubicin; Drug Ev | 1983 |
[Effects of long-term administration of Tegafur on patients with relapsing advanced carcinoma (stage D) of the prostate].
Topics: Aged; Estrogens; Fluorouracil; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Recurrence, Lo | 1983 |
Chemotherapy programs of the National Prostatic Cancer Project (NPCP).
Topics: Antineoplastic Agents; Cyclophosphamide; Dacarbazine; Diethylstilbestrol; Drug Evaluation; Drug Ther | 1980 |
Orchiectomy and chemotherapy with estramustine, cis-platinum, cyclophosphamide, and 5-fluorouracil in newly diagnosed prostate cancer with bone metastases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Castration; Cisplatin; Combined Moda | 1984 |
Chemotherapy of hormone-refractory carcinoma of prostate with 5-fluorouracil, adriamycin, and mitomycin C.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Castration; Doxorubicin; Estro | 1984 |
Treatment of hormone-resistant metastatic carcinoma of the prostate with 5-FU, doxorubicin, and mitomycin (FAM'): a preliminary report.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Fluorouracil; Humans; Male; Middl | 1983 |
Early combined hormonal and chemotherapy for metastatic prostatic carcinoma.
Topics: Aged; Bone Neoplasms; Carcinoma; Castration; Cyclophosphamide; Diethylstilbestrol; Fluorouracil; Hum | 1983 |
Doxorubicin, mitomycin, and 5-FU (DMF) in the treatment of hormone-resistant stage D prostate cancer: a preliminary report.
Topics: Adenocarcinoma; Bone Neoplasms; Doxorubicin; Drug Therapy, Combination; Fluorouracil; Humans; Lung N | 1982 |
Chemotherapy of hormone-resistant stage D prostatic cancer.
Topics: Cisplatin; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Drug Therapy, Combination; E | 1980 |
New agents for prostatic carcinoma.
Topics: Adamantane; Alkylating Agents; Antimetabolites, Antineoplastic; Antineoplastic Agents; Cisplatin; Es | 1981 |
Castration--chemotherapy treatment of prostate cancer model.
Topics: Animals; Carmustine; Castration; Cell Transformation, Neoplastic; Cisplatin; Cyclophosphamide; Disea | 1981 |
Estramustine phosphate with multiple cytotoxic agents in treatment of advanced prostatic cancer.
Topics: Adenocarcinoma; Antineoplastic Agents; Cisplatin; Cyclophosphamide; Drug Therapy, Combination; Estra | 1981 |
Triple drug chemotherapy in treatment of prostate adenocarcinoma Nb Pr A.I.-III.
Topics: Adenocarcinoma; Animals; Carmustine; Cyclophosphamide; Doxorubicin; Drug Combinations; Drug Therapy, | 1981 |
Cooperative clinical trials in prostate cancer.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Doxorubicin; Fluorouracil; Hormones; Humans; Male; | 1981 |
Evaluation of nonhormonal cytotoxic chemotherapy in the Nb rat prostate adenocarcinoma: autonomous tumor (18-Pr and 13-Pr).
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Cyclophosphamide; Dactinomycin; Doxorubicin; Drug Ev | 1980 |
Unusual pigmentary changes associated with 5-fluorouracil therapy.
Topics: Fluorouracil; Humans; Male; Middle Aged; Pigmentation Disorders; Prostatic Neoplasms | 1980 |
Evaluation of chemotherapeutic responsiveness in Nb rat prostate cancer model. 5-fluorouracil, methotrexate, cyclophosphamide, and adriamycin.
Topics: Animals; Cyclophosphamide; Doxorubicin; Fluorouracil; Male; Methotrexate; Neoplasms, Experimental; P | 1980 |
Early combined hormonal and chemotherapy for metastatic carcinoma of prostate.
Topics: Aged; Castration; Cyclophosphamide; Diethylstilbestrol; Drug Therapy, Combination; Fluorouracil; Hum | 1980 |
The non-hormone chemotherapy of prostatic cancer.
Topics: Bone Neoplasms; Cyclophosphamide; Drug Therapy, Combination; Fluorouracil; Humans; Lung Neoplasms; M | 1980 |
Raloxifene (LY156758) produces antimetastatic responses and extends survival in the PAIII rat prostatic adenocarcinoma model.
Topics: Adenocarcinoma; Adrenal Glands; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Dis | 1995 |
Biomodulation of 5-Fu cytotoxicity by folinic acid and its stereoisomers: in vitro experiments with different cell lines of prostatic cancer.
Topics: Antineoplastic Agents; Drug Synergism; Fluorouracil; Humans; Leucovorin; Male; Prostatic Neoplasms; | 1995 |
Angiogenesis inhibitor TNP-470 (AGM-1470) potently inhibits the tumor growth of hormone-independent human breast and prostate carcinoma cell lines.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplas | 1993 |
The synergistic and antagonistic effects of cytotoxic and biological agents on the in vitro antitumour effects of suramin.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Divisi | 1994 |
Laparoscopic intestinal stomas.
Topics: Adenocarcinoma; Adult; Aged; Anus Neoplasms; Carcinoma, Squamous Cell; Colonic Diseases; Colostomy; | 1994 |
The importance of continued endocrine treatment during chemotherapy of hormone-refractory prostate cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocol | 1997 |
[Outpatient chemotherapy with continuous intravenous infusion for patients with recurrent renal cell carcinoma or advanced prostate carcinoma].
Topics: Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; | 1997 |
Effects of combined treatment of chemotherapeutics and hyperthermia on survival and the regulation of heat shock proteins in Dunning R3327 prostate carcinoma cells.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Cell Survival; Cisplatin; Combined | 1998 |
Benzylacyclouridine enhances 5-fluorouracil cytotoxicity against human prostate cancer cell lines.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Drug Inter | 1998 |
[Intraarterial chemotherapy via reservoir system for far-advanced bladder and prostate cancer].
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, | 1998 |
Assessing the impact of chemotherapy on tumor-related symptoms in advanced colorectal cancer.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials, Phase II as Topic; Colorectal Neop | 1998 |
Establishment and characterization of a prostatic small-cell carcinoma cell line (PSK-1) derived from a patient with Klinefelter syndrome.
Topics: Adult; Animals; Antineoplastic Agents; Carcinoma, Small Cell; Cell Division; Cisplatin; Dacarbazine; | 2000 |
Antisense suppression of proline-directed protein kinase FA enhances chemosensitivity in human prostate cancer cells.
Topics: Antineoplastic Agents; Carboplatin; Cell Survival; Cisplatin; DNA, Antisense; DNA, Complementary; DN | 2000 |
Treatment of stage D2 hormone refractory carcinoma of the prostate with 5-fluorouracil and Roferon-A: a Southwest Oncology Group study.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Fluorouraci | 1996 |
Fibroblast growth factors: an epigenetic mechanism of broad spectrum resistance to anticancer drugs.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Cell Division; Culture Media, Conditioned; Doxorubic | 2000 |
Tubulocystic clear cell adenocarcinoma arising within the prostate.
Topics: Adenocarcinoma, Clear Cell; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Fluor | 2000 |
[Development of molecular targeting drugs for the treatment of cancer-therapeutic potential and issues to be addressed in global development].
Topics: Angiogenesis Inhibitors; Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Non-Small-Cell Lung; | 2000 |
Comparison of the malignant phenotype and genotype of the human androgen-independent cell line DU 145 and a subline derived from metastasis after orthotopic implantation in nude mice.
Topics: Androgens; Animals; Antineoplastic Agents; Brain Neoplasms; Cell Division; Chromosome Aberrations; C | 2001 |
External beam radiotherapy for synchronous rectal and prostatic tumors.
Topics: Adenocarcinoma; Aged; Chemotherapy, Adjuvant; Fluorouracil; Follow-Up Studies; Humans; Male; Neoplas | 2001 |
Chemo-cryo combination therapy: an adjunctive model for the treatment of prostate cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Death; Chemotherapy, Adjuvant; Combined Modality Ther | 2001 |
Antineoplastic effects of chemotherapeutic agents are potentiated by NM-3, an inhibitor of angiogenesis.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Aorta; Breast Neoplasms; Cell Movement; Cou | 2002 |
Allopurinol modulation of high-dose fluorouracil toxicity.
Topics: Administration, Oral; Allopurinol; Drug Antagonism; Drug Therapy, Combination; Female; Fluorouracil; | 1979 |
Immunobiology and therapeutic manipulation of heterotransplanted Nb rat prostatic adenocarcinoma. Chemotherapy of autonomous tumor, 102 Pr, heterotransplanted into congenitally athymic (nude) mice and syngeneic Nb rats.
Topics: Adenocarcinoma; Animals; Fluorouracil; Male; Mice; Mice, Nude; Neoplasm Transplantation; Neoplasms, | 1979 |
The chemotherapy of urologic cancer.
Topics: Adenocarcinoma; Adult; Aged; Alkylating Agents; Antineoplastic Agents; Doxorubicin; Drug Therapy, Co | 1975 |
Chemotherapy of advanced prostatic cancer by the National Prostatic Cancer Group.
Topics: Antineoplastic Agents; Cyclophosphamide; Dacarbazine; Fluorouracil; Humans; Male; Procarbazine; Pros | 1976 |
Chemotherapy of advanced prostatic cancer today.
Topics: Aged; Castration; Cyclophosphamide; Doxorubicin; Drug Therapy, Combination; Estramustine; Fluorourac | 1976 |
Chemotherapy of urogenital cancer.
Topics: Adenocarcinoma; Adult; Child; Cyclophosphamide; Dactinomycin; Doxorubicin; Female; Fluorouracil; Hum | 1976 |
Chemotherapy of Nb rat adenocarcinoma of the prostate heterotransplanted into congenitally athymic (nude) mice: report of 5-fluorouracil and cyclophosphamide.
Topics: Adenocarcinoma; Animals; Cyclophosphamide; Disease Models, Animal; Fluorouracil; Male; Mice; Mice, N | 1979 |
Sequential polychemotherapy for advanced prostatic carcinoma. A preliminary cooperative study on 30 patients.
Topics: Cyclophosphamide; Doxorubicin; Drug Therapy, Combination; Fluorouracil; Humans; Male; Neoplasm Metas | 1979 |
The effect of 5-fluorouracil and adriamycin on heterotransplantation of Noble rat prostatic tumors in congenitally athymic (nude) mice.
Topics: Adenocarcinoma; Animals; Doxorubicin; Fluorouracil; Male; Mice; Mice, Nude; Neoplasm Transplantation | 1979 |
Therapeutic manipulation of Nb rat prostatic adenocarcinomas: chemotherapeutic evaluation of autonomous tumors.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Cyclophosphamide; Doxorubicin; Evaluation Studies as | 1979 |
Cyclophosphamide, doxorubicin hydrochloride and 5-fluorouracil in advanced carcinoma of the prostate.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Bone Neoplasms; Cyclophosphamide; Doxorubicin; Drug The | 1979 |
Prostate adenocarcinoma model: Nb rat chemotherapy.
Topics: Adenocarcinoma; Animals; Castration; Cyclophosphamide; Dactinomycin; Disease Models, Animal; Doxorub | 1979 |
Chemotherapy trial with comp-F regimen in advanced adenocarcinoma of prostate.
Topics: Adenocarcinoma; Antineoplastic Agents; Cyclophosphamide; Drug Therapy, Combination; Fluorouracil; Hu | 1978 |
Further experience with chemotherapy in the Dunning prostatic adenocarcinoma.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Asparaginase; Cyclophosphamide; Dactinomycin; Doxoru | 1978 |
Use of arterial infusion of 5-fluorouracil either alone or in combination with supervoltage radiation as a treatment for carcinoma of the prostate and bladder.
Topics: Adenocarcinoma; Aged; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Drug Administration Sc | 1975 |
Hypoglycemia secondary to metastases to the liver. A case report and review of the literature.
Topics: Aged; Cyclophosphamide; Fluorouracil; Humans; Hypoglycemia; Liver Neoplasms; Male; Neoplasm Metastas | 1977 |
[Combination cytostatic chemotherapy of advanced metastatic cancer of the prostate. A preliminary uncontrolled study].
Topics: Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Bone Marrow Diseases; Cyclophosphamide; Dr | 1977 |
Multiple drug chemotherapy regimen for patients with hormonally-unresponsive carcinoma of the prostate: a preliminary report.
Topics: Administration, Oral; Antineoplastic Agents; Drug Administration Schedule; Drug Evaluation; Drug The | 1977 |
Letter: Serpentine supravenous fluorouracil hyperpigmentation.
Topics: Fluorouracil; Humans; Injections, Intravenous; Male; Middle Aged; Pigmentation Disorders; Prostatic | 1976 |
[Multifactorial immunological treatment of cancer in urology].
Topics: Adenocarcinoma; Adult; Aged; Antibody Formation; Cobalt Radioisotopes; Female; Fluorouracil; Humans; | 1976 |
Doxorubicin hydrochloride, cyclophosphamide, and 5-fluorouracil combination in advanced prostate and transitional cell carcinoma.
Topics: Acid Phosphatase; Adenocarcinoma; Aged; Carcinoma, Transitional Cell; Cyclophosphamide; Doxorubicin; | 1976 |
Serpentine supravenous 5-fluorouracil (NSC-19893) hyperpigmentation.
Topics: Fluorouracil; Humans; Male; Middle Aged; Pigmentation Disorders; Prostatic Neoplasms | 1976 |
Serial carcinoembryonic antigen assays in patients with metastatic carcinoma of prostate being treated with chemotherapy.
Topics: Acid Phosphatase; Adenocarcinoma; Carcinoembryonic Antigen; Drug Therapy, Combination; Fluorouracil; | 1976 |
[Treatment of advanced prostatic cancer].
Topics: Adrenalectomy; Aged; Estrogens; Fluorouracil; Humans; Hypophysectomy; Male; Neoplasm Metastasis; Pro | 1975 |
Arterial infusion of 5-FU as a therapeutic adjunct in the treatment of advanced carcinoma of bladder and prostate.
Topics: Adenocarcinoma; Adult; Aged; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Female; Fluorou | 1975 |
Fifteen years' experience of combined hormone/chemotherapy in metastatic prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Comb | 1992 |
[Phase II study of 5'-DFUR treatment of the bladder and prostatic cancer].
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anorexia; Antineoplastic Agents; Diarrhea; Dru | 1991 |
[Studies on 5-FU concentration in serum and prostate cancer tissue after oral administration of UFT].
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Male; Pr | 1991 |
5-Fluorouracil modulation of radiosensitivity in cultured human carcinoma cells.
Topics: Adenocarcinoma; Colonic Neoplasms; Combined Modality Therapy; Drug Administration Schedule; Fluorour | 1991 |
Initial treatment of prostatic cancer by endocrine measures and cytotoxic drugs.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Combined Moda | 1990 |
[5-Fluorouracil (5-FU) concentration in prostatic tissue of rats and in prostatic cancer patients after oral administration of 5-FU].
Topics: Adenocarcinoma; Administration, Oral; Aged; Aged, 80 and over; Animals; Fluorouracil; Humans; Linear | 1990 |
[Alternating combination chemotherapy (VIP-DMF) in patients with advanced adenocarcinoma of the prostate].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Doxorubicin; Drug A | 1987 |
[Chemotherapy of carcinoma of the prostate and testis: experimental study in vivo and in vitro].
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cell Line | 1988 |
Conventional chemotherapeutic agents combined with DMSO or DFMO in treatment of rat prostate carcinoma.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophos | 1989 |
Advanced prostatic carcinoma: pulmonary manifestations.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Fluorouracil; Hum | 1985 |
Combined therapeutic effects of conventional agents and an immunomodulator, PSK, on rat prostatic adenocarcinoma.
Topics: Adjuvants, Immunologic; Animals; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy P | 1989 |
Phase II trial of combination chemotherapy with fluorouracil (F), doxorubicin (A), and cisplatin (P) (Fap) in hormonally resistant metastatic prostatic adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; Drug E | 1989 |
[Combination chemotherapy with ifosfamide, 5-fluorouracil, cisplatin for stage D2 prostatic cancer].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Fluorouracil; Human | 1989 |
[Chemotherapy of advanced prostate cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bromocriptine; Cisplatin; Combined Modality Therapy; | 1986 |
[Study on the concentration of FT-207 and 5-FU in serum and tissues of bladder tumor and prostatic carcinoma].
Topics: Adult; Aged; Fluorouracil; Humans; Male; Middle Aged; Prostate; Prostatic Neoplasms; Suppositories; | 1986 |
Chemotherapy of hormone-resistant carcinoma of the prostate: 4-epi-rubicin weekly v.s. DMF monthly.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Epirubicin; Fluorouracil; Humans; | 1987 |
Effect of endocrine treatment on prostatic blood flow in patients with prostatic adenocarcinoma.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Castration; Combined Modality Therap | 1988 |
Effects of cyclophosphamide alone and scheduled methotrexate-5-fluorouracil combination chemotherapy on transplantable R-3327 prostatic adenocarcinoma in F1 hybrid male rat.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Fluoroura | 1987 |
Phase II trial of the association of doxorubicin, 5 FU and cis platinum in hormonally unresponsive metastatic carcinoma of the prostate.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; Drug Evaluation; Fluor | 1987 |
The case for early combined hormonal and cytostatic treatment for metastatic prostatic carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Diethyl | 1987 |
Combined hormone-chemotherapy for metastatic prostatic carcinoma. Eleven-year follow-up.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; | 1987 |
[Advanced cancer of the prostate: chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Diethylstilbestrol; Doxorubicin; F | 1986 |
The effects of cyclophosphamide, ketoconazole, aclacinomycin-A, methotrexate, and scheduled methotrexate-5-fluorouracil combination chemotherapy on the transplantable R-3327 prostatic adenocarcinoma in the F1 hybrid male rat.
Topics: Aclarubicin; Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphami | 1985 |
[Experiences with polychemotherapy MAF (mitomycin C, adriablastine, 5-fluorouracil) in progressing metastasized prostate cancer].
Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Fluorourac | 1985 |
Chemotherapy of vesical and prostatic tumours.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Bleomycin; Cobalt Isotopes; Cystitis; Daunorubic | 1971 |
Proceedings: Cancer of the prostate.
Topics: Amides; Antineoplastic Agents; Arginase; Bleomycin; Busulfan; Carbamates; Chromomycins; Cyclic P-Oxi | 1973 |
Arterial infusion of 5-fluorouracil as a treatment for carcinoma of the prostate.
Topics: Aged; Catheterization; Fluorouracil; Humans; Iliac Artery; Injections, Intra-Arterial; Male; Middle | 1974 |
Prostatic tumor acid phosphatase production. Influence of antineoplastic agents.
Topics: Acid Phosphatase; Aged; Alkaline Phosphatase; Antineoplastic Agents; Aspartate Aminotransferases; Bl | 1973 |
Current problems in the use of the oncolytic drugs.
Topics: Antineoplastic Agents; Busulfan; Carcinoma, Squamous Cell; Child; Chlorambucil; Choriocarcinoma; Dac | 1968 |
Cancer chemotherapy in urology.
Topics: Adenocarcinoma; Alkylating Agents; Antibiotics, Antineoplastic; Antimetabolites; Chlorambucil; Cobal | 1971 |
[Cytostatic chemotherapy in carcinomas of prostate and corpus uteri (author's transl)].
Topics: Antineoplastic Agents; Cyclophosphamide; Drug Therapy, Combination; Female; Fluorouracil; Humans; Ma | 1974 |
Host-tumor interactions during 5-fluorouracil therapy for prostatic carcinoma.
Topics: Fluorouracil; Humans; Immunoglobulin A; Immunoglobulin G; Immunoglobulin M; Male; Middle Aged; Neopl | 1974 |
Effects of chemotherapy for prostatic carcinoma on T lymphocyte levels.
Topics: Administration, Oral; Aged; Animals; Cyclophosphamide; Diethylstilbestrol; Erythrocytes; Fluorouraci | 1974 |
The continuous arterial infusion of 5-fluorouracil as a therapeutic adjunct in the treatment of advanced carcinoma of the bladder and prostate. A preliminary report.
Topics: Aged; Carcinoma; Cobalt Isotopes; Dose-Response Relationship, Drug; Dose-Response Relationship, Radi | 1973 |
Primary transitional cell carcinoma of the prostate.
Topics: Aged; Alkaline Phosphatase; Blood Urea Nitrogen; Carcinoma, Transitional Cell; Diethylstilbestrol; F | 1973 |
Proceedings: Rationale and results of primary endocrine therapy in patients with prostatic cancer.
Topics: Androgen Antagonists; Animals; Arginase; Body Weight; Castration; Cyclophosphamide; Cyproterone; Dis | 1973 |
[Trial of combined intermittent chemotherapy in prostatic cancers. Estrogen resistant metastases].
Topics: Antibiotics, Antineoplastic; Bone Neoplasms; Drug Therapy, Combination; Estrogens; Fluorouracil; Fol | 1973 |
Cerebellar ataxia during 5-fluorouracil (NSC-19893) therapy.
Topics: Aged; Breast Neoplasms; Castration; Cerebellar Ataxia; Diagnosis, Differential; Female; Fluorouracil | 1971 |
Cryohypophysectomy: indications, technic, and results.
Topics: Acromegaly; Adenoma, Chromophobe; Adult; Breast Neoplasms; Carcinoma; Castration; Cryosurgery; Cushi | 1967 |
Effect of stilbestrol on the isoenzymes of lactate dehydrogenase in benign and malignant prostatic tissue.
Topics: Antineoplastic Agents; Cyclophosphamide; Dactinomycin; Depression, Chemical; Diethylstilbestrol; Est | 1970 |
[Therapy of testicular tumors and prostatic carcinoma].
Topics: Anti-Bacterial Agents; Antineoplastic Agents; Cobalt Isotopes; Estrogens; Fluorouracil; Humans; Male | 1971 |